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Summary 
 
 
Dengue virus (DENV) is the most significant arthropod-borne virus (arbovirus) of humans, 
primarily transmitted by Aedes aegypti mosquitoes. Currently there are no specific 
therapeutics and the existing vaccine exhibits limited efficacy. Therefore, vector control 
remains the best approach to manage disease spread.  
 
We previously demonstrated that DENV-2 infection does not induce innate immunodeficiency 
(IMD) signalling in the Ae. aegypti Aag2 cell line, recapitulating in vivo data from other groups.  
Furthermore, prior infection with DENV-2 reduces IMD signalling activation by classical 
immune stimuli. This project aimed to identify DENV-2 antagonist(s) responsible for this 
immune inhibition using an RT-qPCR-based screening platform in which IMD signalling is 
stimulated in cells expressing DENV-2 proteins individually. Our results identified NS4A as a 
tentative antagonist, which can now be used to enhance our understanding of Ae. aegypti 
antiviral immunity by investigating virus-host interactions.  
 
The study of vector immunity is hampered by the lack of tools such as antibodies and cell 
lines. Our group previously created CRISPR-Cas9 knockout Aag2 cell lines, which lack genes 
essential in the innate immune pathways. These knockout cell lines were created from clonally 
selected Aag2 cells derived from the heterogeneous parental cell line, and this report also 
describes the final characterisation of these clones. Results confirm that the cells are 
embryonic in origin, which confounded our sex analysis. Aag2 clones were confirmed to be 
persistently infected insect-specific viruses, cell fusing agent virus and Phasi Charoen-like 
virus. Transfection efficiencies were also determined for the clones of interest. Finally, 
mutations introduced by CRISPR-Cas9 were characterised in cells derived from one of the 
clonally selected lines, with one clone identified as the intended mutant, however the IMD 
pathway-deficient cell clones were determined as wild type.  
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Ultimately insights into vector antiviral immunity may contribute towards development of 
transmission-incompetent mosquitoes, thereby reducing the global burden of dengue.  
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1.1 Mosquito-borne Viruses  
Arthropod-borne viruses (arboviruses) are a significant threat to global health, causing some 
of the most serious human infectious diseases, potentially leading to severe manifestations 
such as encephalitis, haemorrhagic fevers and meningitis (Rudolph et al., 2014). Mosquitoes 
are the major vector for many of these viruses throughout the world and their transmission 
leads to hundreds of millions of infections annually (Caraballo and King, 2014). Although the 
majority of mosquito-borne diseases are endemic to tropical and subtropical areas, factors 
such as urbanisation, international travel and global warming have enabled the expansion of 
mosquitoes’ geographical range, therefore increasing the risk of arboviral disease worldwide 
(Yi et al., 2014). 
 
Mosquito-borne viruses are usually maintained in a horizontal transmission cycle between 
mosquitoes and vertebrate hosts (WHO, 1997). Mosquitoes transmit viruses to their hosts via 
blood meals. The vertebrate host replicates the virus to sufficiently high levels of viraemia to 
then be acquired by feeding mosquitoes, thus maintaining the transmission cycle. Once an 
infectious blood meal is ingested, viruses infect and replicate in the midgut epithelium (Figure 
1.1). The virus subsequently spreads through the haemolymph to organs such as the neural 
system, fat body, trachea and the salivary glands. From the salivary glands, the virus is then 
secreted into the saliva, enabling the virus to infect a new host. These viruses cause persistent 
viral infections in the mosquito, through mechanisms which are not fully understood but likely 
involve cellular, immune and viral factors (Riedel and Brown, 1977; Dittmar et al., 1982; 
Oldstone, 2006; Goic et al., 2013). There is evidence that suggests that the generation of viral-
derived DNA from infecting RNA viruses and production of defective interfering particles may 
be involved in viral persistence in mosquitoes (Tsai et al., 2007; Goic et al., 2016). The 
presence of persistent infections may enhance, inhibit or allow accommodation of secondary 
viral infections (Salas-Benito and De Nova-Ocampo, 2015). Replication is non-pathogenic and 
has no dramatic influence on the life span of the mosquito, allowing effective virus 
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transmission (Xiao et al., 2015). The time between the acquisition of a pathogen by the vector 
and the ability to transmit to a susceptible host is known as the extrinsic incubation period 
(EIP). The length of the EIP is dependent on a combination of factors including the virus strain, 
mosquito species, as well as environmental factors such as temperature and humidity (Watts 
et al., 1987; Black et al., 2002). Innate immune responses are key regulators of dissemination 
and viral propagation within the mosquito vector and are therefore a crucial determinant of the 
EIP during infection (Cheng et al., 2016). 
 
Figure 1.1 Dengue virus (DENV) life cycle in the mosquito vector. After ingestion of a blood 
meal from a DENV-infected individual, the virus first has to infect and replicate in the midgut 
epithelium, with peak titres at 7-10 days post-ingestion (dpi). From there the virus disseminates 
into the haemocoel (body cavity) where other organs are infected. The virus reaches the salivary 
glands where it further propagates to high titres, peaking at 12-18 dpi, and can then be secreted 
into the saliva. From this point the mosquito is able to transmit virus upon the next blood meal 
(Salazar et al., 2007) Figure adapted from Coffey et al., (2013) and Dr Kevin Maringer. 
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1.2 Arthropod Innate Immunity 
Arthropods lack adaptive immune responses homologous to those of mammals, but have 
evolved effective innate immune systems to defend against viral, bacterial, parasitic and 
fungal challenges. Three major immune signalling pathways in arthropods include the 
immunodeficiency (IMD), Toll, and Janus kinase/ signal transducers and activators of 
transcription (JAK-STAT) pathways (Figure 1.2; Sim et al., 2014).  
 
 
 
 
 
Figure 1.2 Overview of mosquito inducible innate immunity. Three innate immune responses 
in mosquitoes are the Toll, IMD, and JAK-STAT pathways. Their signalling cascades are induced 
by the recognition of a pathogen-associated molecular pattern (PAMP) by a pattern recognition 
receptor (PRR), neither of which are well defined for mosquito antiviral immunity, leading to the 
downstream activation of their respective transcription factors, Rel1A, Rel2 and STAT, thus inducing 
immune-regulated effector proteins. Image adapted from Dr Kevin Maringer. 
  
 
 
26 
These pathways have been studied mostly in Drosophila melanogaster and orthologues of 
key pathway components with a high degree of similarity have been identified in Aedes aegypti 
mosquitoes (Christophides et al., 2002; Waterhouse et al., 2007; Bartholomay et al., 2010).  
However, as D. melanogaster is not an arbovirus vector it is highly likely that antiviral immune 
responses differ between these species, which is also suggested by the significant 
differentiation of upstream pattern recognition receptors (PRRs) and downstream effectors, 
highlighting the need to decipher the antiviral mechanisms in major mosquito vectors 
(Waterhouse et al., 2007). 
 
1.2.1 IMD Pathway 
IMD signalling shares many similarities with the vertebrate tumour necrosis factor receptor 
(TNFR) signalling pathway (Figure 1.3).  Activation via PRRs leads to a cascade involving the 
degradation of the negative regulator Caspar, allowing the translocation of the nuclear factor 
kappa-light-chain-enhancer of activated B cells (NF-κB) transcription factor Rel2 to the 
nucleus to promote the expression of effectors and antimicrobial peptides (AMPs), such as 
defensins and cecropins (Merkling and van Rij, 2013; full pathway described in Figure 1.3).  
The pathway is best characterised for its induction by the diaminopimelic acid (DAP)-type 
peptidoglycan, a cell wall constituent of Gram negative bacteria, and its downstream 
antibacterial mechanisms (Choe et al., 2002). The role of the IMD response in antiviral 
immunity is poorly characterised and its pathogen associated molecular patterns (PAMPs) 
and PRRs have yet to be elucidated. Some AMPs found to be upregulated by IMD signalling 
are potent antiviral effectors (Luplertlop et al., 2011; Pan et al., 2012), suggesting the 
involvement of the pathway in antiviral responses, although the mechanisms of these peptides 
remain unknown (Merkling and van Rij, 2013). It has been shown in D. melanogaster that the 
IMD pathway has antiviral functions against infection with cricket paralysis virus (CrPV), 
Sindbis virus and Drosophila melanogaster sigma virus (Tsai et al., 2008; Costa et al., 2009; 
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Figure 1.3 Mosquito IMD signalling and mammalian TNFR signalling homologues. Viral 
PAMPs are sensed by PRRs, which are unknown in Ae. aegypti. Immunodeficiency (IMD) and Fas-
associated death domain (FADD) proteins are then recruited to activate the caspase Dredd. Dredd 
cleaves the IMD pathway transcription factor Rel2 in a phosphorylation-dependent manner, which 
allows the N-terminal Rel2 domain to translocate into the nucleus and initiate downstream 
transcription of immune genes (e.g. AMPs). The C-terminal inhibitor IκB domain remains in the 
cytoplasm. Phosphorylation of Rel2 occurs following IMD cleavage, enabling IMD to bind the 
inhibitor of apoptosis 2 (IAP2), which then recruits and activates the IκB kinase (IKK) complex 
through K63 ubiquitin conjugation. The IMD pathway negative regulator, Caspar, inhibits Rel2 
cleavage. Ae. aegypti (Aa) IMD pathway components and Homo sapiens (Hs) homologues from 
TNFR signalling are listed.  Image from Dr Kevin Maringer. 
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Avadhanula et al., 2009). In mosquitoes, upregulation of many IMD pathway components 
within the Ae. aegypti salivary glands upon dengue virus (DENV) infection has also been 
observed (Luplertlop et al., 2011).  
 
1.2.2 Toll Pathway 
The Toll pathway resembles mammalian Toll-like receptor (TLR) signalling and follows a 
cascade similar to the IMD response, where upregulation of AMPs is induced by the nuclear 
translocation of an NF-κB transcription factor, Rel1A (Sim et al., 2014). Although the 
antibacterial and antifungal mechanisms of the pathway have been deciphered, the extent of 
the Toll pathway’s antiviral capabilities are not yet fully understood. However, studies have 
found that Toll signalling plays a role in restricting DENV replication (Xi et al., 2008). 
 
1.2.3    JAK-STAT Pathway 
In comparison to the IMD and Toll pathways, less is known about the mosquito JAK-STAT 
pathway, particularly with regards to signalling activation and downstream effectors (Cheng et 
al., 2016).  The key signalling components of the mammalian and arthropod JAK-STAT 
pathway are evolutionally conserved, and like the interferon-stimulated response in 
vertebrates, mosquito JAK-STAT is involved in antiviral defence (Sim et al., 2014).  
 
1.3 Mammalian Innate Immunity 
1.3.1   NF-κB Signalling Pathway 
The NF-κB signalling pathway evolved over 500 million years ago and since then has co-
evolved to result in the current homologous signalling pathways between vertebrate and 
invertebrate systems (Wang et al., 2006). The NF-κB family of transcription factors is a small 
family of proteins that play a critical role in inflammation and regulation of immune responses 
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to infection. In mammals, NF-κB exists as homo- or heterodimers of p65/RelA, RelB, c-Rel, 
p105/p50 (NF-κB1), or p100/p52 (NF-κB2) (Zhang et al., 2017a). These dimers are held in an 
inactive complex with one of a family of inhibitory proteins known as the inhibitors of kappa B 
(IκBs), within the cytoplasm (Ghosh et al., 1998). Upon degradation of the IκB, the nuclear 
localisation signal of NF-κB is revealed and nuclear translocation can occur, where they 
activate the transcription of effector genes (Zhang et al., 2017a). 
 
1.3.2    Comparison of Mammalian TNFR and Mosquito IMD Signalling Pathways 
The mosquito IMD immune response is similar to the mammalian TNFR signalling pathway 
with many of the molecular components and signalling events conserved, as highlighted in 
Figure 1.3 and Table 1.1 (Myllymäki et al., 2014). A major difference between the two systems 
is the transcription factor activation. As stated previously, the mammalian NF-κB (p105/p110) 
dimer is held in an inactive state by the IκB protein until pathway activation induces 
proteasomal degradation of IκB, which in turn results in NF-κB activation and nuclear 
translocation (Zhang et al., 2017a). In contrast, the mosquito NF-κB (Rel2) and the inhibitor 
IκB exists as one protein, with the inhibitory domain present at the C-terminal end (Myllymäki 
et al., 2014). Once the IκB domain is cleaved by Dredd, IκB is released, permitting Rel2 
nuclear translocation.  
 
Upstream sensing also differs between mammalian and insect systems, with TNFRs being 
cytokine receptors that recognise the inflammatory cytokine TNF-α. From bacterial sensing it 
is known that IMD receptors are PRRs which sense Gram negative DAP-type peptidoglycan 
(Choe et al., 2002), although how viruses are sensed remains unknown. The pathways also 
differ in downstream genes induced, with cytokines such as interferons (IFNs) being induced 
in mammalian systems (Tseng et al., 2018). There is no recognised equivalent of IFNs in 
mosquitoes, with only one group reporting orthologues of the Drosophila spp. IFN-like cytokine 
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1 Information is based on mosquito immune studies, not solely on Drosophila pathway extrapolation. 
 
 
Vago in mosquito species including Aedes albopictus (Paradkar et al., 2012). Upon 
stimulation, AMPs such as defensins and cecropins are largely upregulated in mosquito 
systems although through which pathway these AMPs are upregulated by may be tissue-
dependent (Sim et al., 2014).  
 
 Human TLR Mosquito1 Toll Human TNFR Mosquito1 IMD 
Receptor type PRR Cytokine receptor Cytokine receptor PRR 
Agonists (or 
known viral 
PAMPs) 
dsRNA1, 
envelope 
glycoproteins2, 
ssRNA3, CpG 
DNA4 
Spätzle  sTNF-α5, 
mTNF-α6 
 
Not known 
Receptors/viral 
PRRs 
TLR31, TLR42, 
TLR7/83, TLR94 
Not known TNFR15,6, 
TNFR26 
Not known 
Major 
transcription 
factor 
activation 
event 
IκBα protein is 
cleaved from NF-
κB (p50/p65) 
dimer and is 
degraded by the 
proteasome, 
allowing NF-κB 
nuclear 
translocation. 
Phosphorylation 
and subsequent 
ubiquitination 
leads to 
degradation of 
negative 
regulator Cactus, 
allowing Rel1A 
nuclear 
translocation. 
IκBα protein is 
cleaved from NF-
κB (p105/p110) 
dimer and is 
degraded by the 
proteasome, 
allowing NF-κB 
nuclear 
translocation. 
Dredd cleaves 
IκB domain of 
phosphorylated 
Rel2 in the 
absence of 
negative 
regulator Caspar, 
allowing Rel2 
nuclear 
translocation. 
Induced 
effectors 
Type I 
interferons, 
inflammatory 
cytokines, 
chemokines, 
adhesion 
molecules, 
AMPs, inducible 
nitric oxide 
synthetase 
AMPs 
(Defensins, 
cecropins, 
lysozyme) 
Caspases, anti-
apoptotic proteins 
(cFLIP), 
inflammatory 
cytokines, 
chemokines 
AMPs 
(Defensins, 
cecropins, 
gambicin) 
 
Table 1.1 Comparison of human and mosquito signalling pathways. Jang et al., 2006; Shin et 
al., 2006; Xi et al., 2008; Antonova et al., 2009; Mogensen 2009; Zhang et al., 2017b; Tseng et al., 
2018. 
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1.4 Flaviviruses 
The Flavivirus genus belongs to the Flaviviridae family of positive-sense RNA viruses (Knipe 
and Howley, 2013). Many significant arboviruses belong to this group, with 40 of the 53 
currently recognised Flavivirus species being known to cause important human diseases (King 
et al., 2012; ICTV, 2018). These include yellow fever virus (YFV), Zika virus (ZIKV), Japanese 
encephalitis virus (JEV), West Nile virus (WNV) and DENV, all of which are transmitted by 
Aedes or Culex mosquito vectors.  
 
1.5 Dengue Virus 
1.5.1   DENV Prevalence and Impact  
Dengue is a neglected tropical disease and the most prevalent arboviral disease in humans 
with 3.9 billion people, almost half of the global population, at risk of infection (Deen et al., 
2006; Brady et al., 2012). Infections can be asymptomatic in up to 75% of cases but can also 
manifest as self-limited dengue fever or potentially fatal dengue haemorrhagic fever (DHF) 
and dengue shock syndrome (DSS) (Diamond and Pierson, 2015). Dengue is endemic in 
more than 100 countries, mainly in tropical and sub-tropical regions, with an estimated 390 
million infections annually (Bhatt et al., 2013). Of the estimated infections, there are ~96 million 
cases with clinical manifestations of any severity and ~500,000 hospitalisations for DHF/DSS, 
the majority of which are children (Guzman et al., 2010; Bhatt et al., 2013).  
 
1.5.2    Transmission Vectors  
The primary vector facilitating DENV transmission is Ae. aegypti and to a lesser extent, Ae. 
albopictus, both of which are also vectors for other significant arboviruses such as YFV, ZIKV 
and the alphavirus, chikungunya virus (CHIKV). The prevalence of DENV reflects the 
geographical distribution of its vectors (Figure 1.4), making mosquito density an important 
parameter for predicting DENV outbreaks (WHO, 1997). Ae. aegypti is one of the most 
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significant vectors of human arboviral diseases as they thrive in urban environments and feed 
almost exclusively on humans (Harrington et al., 2001; Powell and Tabachnick, 2013). 
Females take multiple blood meals within a gonadotrophic cycle, therefore an infected 
mosquito is capable of infecting multiple hosts, enabling Ae. aegypti to spread DENV 
effectively (WHO, 1997).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 Global distribution of DENV primary and secondary vectors.  Predicted 
occurrence of (a) Aedes aegypti and (b) Aedes albopictus, coloured by probability (0 blue to 1 
red). Figure from Kraemer et al., (2015). 
(a) Aedes aegypti 
(b) Aedes albopictus 
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1.5.3 History of DENV Emergence 
The first appearance of DENV in human populations remains unknown as in most cases the 
disease is asymptomatic and thus remains undiagnosed. The earliest description of a dengue-
like illness was found in a Chinese medical encyclopaedia published during the Jin Dynasty 
between 265-420 AD (Nobuchi, 1979; Gubler, 1998) (Figure 1.5). By the end of the 18th 
century there had been intermittent outbreaks of dengue-like disease reported in Asia and the 
Americas (Gubler et al., 1998). Throughout the 1800s to mid-1900s, major dengue fever 
epidemics were reported in many parts of the world including the United States of America 
(1970, 1922) Zanzibar (1823, 1870), Calcutta (1824, 1853, 1871, 1905), West Indies (1827), 
Hong Kong (1901), Australia (1925-26, 1942), Greece (1927-1928) and Japan (1942-1945) 
(Henchal and Putnak, 1990). This expansion of disease distribution is believed to be attributed 
to the spread of the Ae. aegypti mosquito vector, originating from West Africa (Sylla et al., 
2009), by its transportation on shipping vessels to the Americas and southeast Asia (Weaver 
and Reisen, 2010). Due to the similarities of clinical symptoms presenting from both DENV 
and CHIKV infection, it is widely disputed whether all these epidemics can be attributed to 
DENV (Henchal and Putnak, 1990) although the clinical description of the 1790 epidemic in 
Philadelphia, United States is thought to be the first described that is likely to have been 
caused by DENV (Rush, 1789; Halstead, 2015).  
 
With the movement of troops throughout southeast Asia and Pacific regions during World War 
II (1939-1945), increased transmission and the circulation of multiple serotypes 
(hyperendemicity) lead to the emergence of a novel dengue-like disease of increased severity, 
initially in the endemic regions of southeast Asia (Gubler et al., 1998). The first reported 
epidemic of this severe form of dengue, which came to be known as DHF, occurred in the 
Philippines (1953-1954) (Hammon et al., 1960) and by the mid-1970s, DHF was the leading 
cause of hospitalisation and death in the region (WHO, 1986). DHF epidemics soon spread to 
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the Western Pacific region with the first well-documented epidemic occurring in Malaysia 
(1975) (Gubler, 1998).  
 
Dengue epidemics were rare in the Americas after World War II due to the Aedes aegypti 
eradication campaign initiated in 1946 by the Pan American Health Organisation in a bid to 
control urban yellow fever (Gubler, 1998; Weaver and Reisen, 2010). The US federal 
government launched a similar initiative in 1965 (Slosek, 1986). Mosquito breeding sites and 
their surroundings were treated with dichlorodiphenyltrichloroethane (DDT) which successfully 
eradicated Ae. aegypti from 22 countries throughout the Americas (Reiter, 2010).  However, 
in the early 1970s both eradication programmes were suspended due to lack of political will 
and funding (Slosek, 1986; Hotez, 2016).  Ae. aegypti soon reinvaded the Americas, followed 
by the introduction of new dengue serotypes and strains, leading to hyperendemicity and the 
emergence of DHF epidemics by the 1980s (Gubler, 1998).  
 
Over the following decades, dengue incidence and geographical spread increased as did the 
number of DHF cases. Global demographic, environmental and societal changes such as 
long-distance air travel, population growth and urbanisation have been the primary driving 
forces responsible for the dramatic resurgence of dengue in the later years of the 20th century 
(Gubler, 2002). 
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Figure 1.5 Timeline of dengue emergence. Asterisk (*) represents unconfirmed dengue epidemics. Gubler, 1998; Henchal and 
Putnak, 1990; Rush, 1789; Weaver and Reisen, 2010; WHO, 1986. 
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1.5.4    Molecular Biology of DENV 
DENV is an enveloped, single-stranded positive sense RNA virus with an ~11 kb genome that 
contains a single open reading frame encoding three structural proteins – capsid (C), 
precursor of membrane/ membrane (prM/ M) and envelope (E) – as well as seven non-
structural proteins – NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5 (Figure 1.6). The open 
reading frame is flanked by 5’ and 3’ untranslated regions (UTRs) that contain characteristic 
secondary structures, which serve various functions and are necessary for efficient replication 
(Gamarnik et al., 2010).  
 
Four DENV serotypes exist (DENV-1 to -4) that have a limited similarity at the amino acid level 
(60-75% amino acid sequence homology) (Fu et al., 1992), with reported differences in 
disease severity related to serotype (Vicente et al., 2016).  
 
 
 
 
 
 
 
Figure 1.6 Genomic organisation of DENV. The single-stranded positive sense genome 
organisation and single open reading frame encoding for three structural proteins and seven non-
structural proteins is illustrated. The 5’ UTR contains a 7-methyl guanosine cap and the 3’ UTR 
lacks a poly(A) tail. Image adapted by Dr Kevin Maringer from Clyde et al., (2006). 
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1.5.5 DENV Replication Cycle 
1.5.5.1 Binding and entry 
Upon the bite of a DENV-infected mosquito, the proboscis pierces through the skin and upon 
reaching a blood vessel, releases saliva containing anticoagulants as well as DENV into the 
bloodstream (Ribeiro and Francischetti, 2003). DENV binds to host target cells via an 
undefined receptor (Figure 1.7), although putative receptors include, but are not limited to, 
DC-SIGN, heparan sulfate, mannose, CD14, and HSP70/90 (Clyde et al., 2006). Dendritic 
cells, monocytes, endothelial cells, fibroblasts, macrophages, and mast cells are permissible 
to DENV infection in vitro (Clyde et al., 2006). Upon the DENV E glycoprotein binding to its 
receptor, the virus enters the cell via clathrin-mediated endocytosis (Lindenback et al., 2007). 
A drop in the endosomal pH triggers a conformational change of the E protein from a dimeric 
to trimeric form thereby exposing the E fusion peptide (Bressanelli et al., 2004), triggering 
virus-endosomal membrane fusion and release of the nucleocapsid into the cytoplasm 
(Lindenbach et al., 2007). 
 
1.5.5.2 Translation and genome replication  
Following nucleocapsid uncoating, input positive-sense viral RNA (vRNA) is released into the 
cytoplasm, which must first be translated to generate the NS5 viral RNA replicase protein 
before genome replication can occur (Tan et al., 1996). DENV vRNA is translated by host 
ribosomes associated with ER membrane structures. Like mRNA, the DENV vRNA contains 
a 5’ type I 7-methyl guanosine (7mG) cap structure, yet unlike mRNA it lacks a poly(A) tail 
(Clyde et al., 2006). The resultant polyprotein is weaved through the ER membrane where it 
is co- and post-translationally cleaved into individual viral proteins by the host proteases furin 
and signalase, and by the viral protease complex NS2B-NS3 (NS2B/3) (Figure 1.8; 
Lindenbach and Rice, 2003). Structural proteins prM and E assemble in the ER lumen, 
whereas the non-structural proteins localise in virus-induced membrane vesicles where RNA 
synthesis occurs (Welsch et al., 2009). 
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Figure 1.7 Overview of the DENV replication cycle. (1) DENV E protein binds to an undefined 
host receptor. (2) DENV virion enters the permissive cell via clathrin-mediated endocytosis. (3) 
Acidification of the endosome leads to virus-host membrane fusion and nucleocapsid release into 
the cytosol. (4) Following nucleocapsid uncoating, vRNA is translated by host ribosomes and the 
resultant polyprotein is co- and post-translationally cleaved by host proteases and the viral protease 
complex, NS2B/3. (5) Formation of viral replication complexes containing all non-structural proteins 
permitting vRNA replication to occur. (6) Newly synthesised vRNA interacts with capsid proteins to 
form the nucleocapsid. (7) The nucleocapsid buds into the ER lumen, thereby enveloping the 
nucleocapsid in ER membrane containing structural proteins prM and E. (8) Immature virus particles 
move along the trans-Golgi network where furin proteases cleave prM to form pr and M, thereby 
creating mature virus particles. (9) Virus particles are released from the cell by exocytosis and the 
pr cleavage product disassociates from the particle. Image adapted from MicrobiologyNotes (2019). 
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After DENV translation and cleavage, a switch from translation to genome replication occurs 
in which a negative-sense RNA intermediate, the antigenome, is transcribed that subsequently 
acts as a template for the synthesis of new positive-sense vRNA (Clyde et al., 2006). vRNA 
synthesis is described as asymmetric, as positive-sense vRNA accumulates in tenfold excess 
compared to the negative-sense antigenome (Lindenbach et al., 2007).  
 
DENV infection induces invaginations of the ER membrane mainly via NS4A to form various 
membranous structures including vesicle packets and convoluted membranes (Grief et al., 
1997; Welsch et al., 2009). Vesicle packets act as a scaffold for the viral replication complex 
(VRC), which may provide an environment shielded from host defence sensors and promote 
efficient replication by anchoring the replication machinery to membrane structures (Netherton 
et al., 2007). The VRC contains vRNA, viral proteins, and likely host cell factors necessary for 
replication (Welsch et al., 2009). These membrane structures are not completely sealed as 
they contain a pore, which may permit the entry of nucleotides and host factors necessary for 
replication and the release of newly-synthesised vRNA into the cytosol for translation and virus 
assembly (Welsch et al., 2009).  
Figure 1.8 DENV polyprotein. The polyprotein contains the three structural and seven non-
structural proteins and is co- and post-translationally cleaved by host proteases within the ER 
lumen and the viral protease complex NS2B/3 in the cytoplasm. Arrows indicate protease cleavage 
sites. Image adapted from de Almeida et al., (2013).  
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All non-structural proteins are located within the VRC (Welsch et al., 2009) and have essential 
roles in viral replication. NS1 is present in monomeric, dimeric and hexameric forms during 
DENV infection and is essential for replication, yet its precise functions remain elusive 
(Mackenzie et al., 1996; Muller et al., 2013). Like NS1, NS2A and NS4B have been shown to 
have essential roles in virus replication but their exact functions are unknown (Miller et al., 
2006; Xie et al., 2015). As previously stated, NS4A induces ER membrane rearrangements 
but also interacts with NS4B, potentially modulating a switch between replication stages (Miller 
et al., 2007; Zou et al., 2015). Unlike the above-mentioned non-structural proteins both NS3 
and NS5 are known to have essential enzymatic functions. As well as its serine protease 
activity, NS3 has nucleoside triphosphatase and helicase functions required for vRNA 
synthesis (Li et al., 1999), and a 5’ triphosphatase function for 7mG capping of vRNA. NS5 
exhibits viral RNA-dependent RNA polymerase and methyl transferase functions (Tan et al., 
1996; Egloff et al., 2002), the latter being required for vRNA capping.  
 
1.5.5.3 Assembly, maturation and egress 
Following protein translation and genome replication, newly synthesised vRNA interacts with 
C proteins to form the nucleocapsid and is recruited to the ER (Mukhopadhyay et al., 2005). 
The nucleocapsid buds into the ER lumen and is enveloped by the ER membrane containing 
prM-E heterodimers, forming immature virus particles that are transported along the secretory 
pathway through the trans-Golgi network (TGN) (Wengler and Wengler, 1989). The acidic 
environment of the TGN induces a rearrangement of the prM and E glycoproteins, which 
consequently exposes prM for its subsequent cleavage into pr and M by the host protease 
furin (Shapiro et al., 1972). The cleaved pr peptide partially covers E to prevent premature 
fusion or inactivation whilst in the acidic environment of the secretory pathway (Guirakhoo et 
al., 1992) therefore pr remains associated with the virion whilst located in the TGN (Yu et al., 
2008).  The mature, infectious virions are released from the cell by exocytosis and the pr 
proteolytic product dissociates from the virus particle (Yu et al., 2008). 
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1.5.6 Host Innate Immune Responses and DENV Viral Antagonists 
1.5.6.1 Mammalian Host Innate Immune Responses 
The IFNs are a family of secreted cytokines that induce an antiviral response upon infection 
of mammalian cells (Randall and Goodbourn, 2008). DENV infection triggers type I IFN 
induction through the sensing of viral RNA by TLR and retinoic acid-inducible gene I (RIG-I)-
like receptors, initiating their signalling cascades. Type I IFN production subsequently induces 
the JAK-STAT-dependent IFN signalling pathway which results in the upregulation of 
hundreds of IFN stimulated genes (ISGs), some of which are capable of inhibiting DENV at 
various points in the viral replication cycle (Ramirez and Urcuqui-Inchima, 2015). However, it 
has been found that some DENV proteins target and antagonise key components of the IFN 
induction and signalling pathways.  
 
The DENV NS2B protein has been shown to inhibit IFN induction through the binding and 
lysosomal degradation of the DNA sensor cyclic GMP-AMP synthase (cGAS), thereby 
avoiding mitochondrial DNA sensing during infection (Aguirre et al., 2017). The DENV viral 
protease NS2B/3 targets and cleaves human adaptor molecule stimulator of interferon genes 
(STING), thereby preventing phosphorylation of interferon regulatory factor-3 (IRF-3) and the 
subsequent activation of the IFN-β promoter (Aguirre et al., 2012). Additionally, the NS4A 
protein interacts with the mitochondrial antiviral signalling protein (MAVS) and prevents it’s 
binding to RIG-I, thereby repressing RIG-I-mediated IRF-3 activation and subsequent IFN 
induction (He et al., 2016). The IFN signalling pathway can also be antagonised by DENV 
proteins, with NS4B preventing signal transducer and activator of transcription (STAT) 1 
phosphorylation (Munoz-Jordan et al., 2005) and NS5 targeting STAT2 for proteasomal 
degradation (Ashour et al., 2010). DENV subgenomic flaviviral RNAs (sfRNAs) have also been 
shown to inhibit IFN responses during viral infection, by antagonising host proteins G3BP1, 
G3BP2, and CAPRIN1 which have suggested roles in the translation and regulation of ISGs, 
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and TRIM25, a modulator of the type I IFN response (Bidet et al., 2014; Manokaran et al., 
2015).  
 
1.5.6.2 Insect Host Innate Immune Reponses 
In the primary vector Ae. aegypti, DENV infection activates Toll and JAK-STAT signalling 
pathways, with two JAK-STAT pathway-related dengue restriction factors identified; dengue 
virus restriction factor (DVRF) 1 and 2 (Xi et al., 2008; Souza-Neto, et al., 2009). Previous 
microarray analyses of DENV-2 infected mosquitoes showed a lack of IMD pathway gene 
upregulation which may be due to lack of pathway stimulation or active antagonism by the 
virus (Xi et al., 2008). The major insect antiviral pathway, RNAi is also activated upon infection 
and has been shown to limit DENV replication (Sanchez-Vargas et al., 2009). However, it has 
also been found that flavivirus sfRNAs are able to suppress mosquito RNAi and Toll activity 
(Schnettler et al., 2012; Moon et al., 2015; Pompon et al., 2017).  
 
1.5.7    Current Therapeutics and Disease Control 
1.5.7.1 Dengue antivirals and vaccines 
There are currently no DENV-specific antiviral therapeutics and the development of an 
effective and safe DENV vaccine is extremely challenging. The only licenced vaccine is 
Dengvaxia® (CYD-TDV), a live-attenuated, recombinant tetravalent vaccine developed and 
manufactured by Sanofi Pasteur, in which the DENV prM and E proteins are inserted into the 
YFV (YF17D) vaccine backbone (Guy et al., 2011). Data pooled from two Phase III clinical 
trials have shown that the vaccine has mixed efficacy, with high efficacies for DENV-3 and -4 
(71.6% and 76.9% respectively) but much poorer against DENV-1 and -2 (54.7% and 43.0% 
respectively), which is particularly problematic as DENV-2 is the most globally relevant 
serotype (Capeding et al., 2014; Villar et al., 2015; Vannice et al., 2016). Benefit-risk studies 
of seronegative individuals indicated that the vaccine increases the risk of DHF/DSS in 
  
 
 
43 
seronegative vaccinees, therefore the vaccine is now recommended only for use in areas of 
high seroprevalence or on a national level if vaccination of seronegative individuals can be 
avoided (WHO, 2018). Due to safety issues, the Strategic Advisory Group of Experts on 
Immunization (SAGE) working group recommends countries to implement a pre-vaccination 
screening strategy, such as the use of the anti-DENV NS1 IgG enzyme-linked immunosorbent 
assay (ELISA) recently developed by Sanofi Pasteur (Nascimento et al., 2018; WHO, 2018). 
However, potential cross-reactivity of other flaviviruses limiting the specificity of screening 
tests as well as the affordability of both a pre-vaccine screening programme and the CYD-
TDV vaccine are major considerations for DENV-endemic countries (Nascimento et al., 2018; 
WHO, 2018), especially those within developing regions.  
 
1.5.7.2 Vector control 
Vector control remains the best approach for controlling the spread of disease. However, 
problems such as insecticide resistance, lack of sustainable interventions and the inability to 
scale up current and previous vector control methods have limited the effectiveness of 
reducing the global dengue burden (Achee et al. 2019). Therefore alternative strategies are 
being developed to overcome these obstacles and control the spread of DENV as well as 
other mosquito-borne arboviruses. Three promising strategies are described below. 
 
1.5.7.2.1 Release of Insects with Dominant Lethality 
The classical sterile insect technique that involves male mosquito sterilisation by irradiation 
has major adverse effects such as reduced competitive mating ability and longevity (Alphey 
and Andreasen, 2002). To overcome this, the release of insects with dominant lethality (RIDL) 
strategy (Thomas et al., 2000) was developed in Ae. Aegypti, which involved the insertion of 
a lethal gene into male mosquitoes resulting in the premature death of their offspring. The 
transgenic construct contains a tetracycline-repressible effector gene which is homozygous, 
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dominant lethal and a DsRed2 fluorescent marker allowing for screening, tracking and 
monitoring of modified mosquitoes through the process of the intervention (Phuc et al., 2007).  
Oxitec have successfully generated a self-limiting strain of Ae. aegypti (OX513A) through the 
integration of the RIDL transgenic construct into laboratory strains (Phuc et al., 2007). Results 
from initial open release trials in Brazil, Panama and the Cayman Islands have shown 
reductions in Ae. aegypti populations of at least 90% (Harris et al., 2011; Harris et al., 2012; 
Carvalho et al., 2015; Gorman et al., 2016), although continued monitoring is needed to 
provide insight into long-term population suppression (Achee et al., 2019). There are also 
concerns that suppression of the Ae. aegypti population could lead to population replacement 
by another mosquito species, such as Ae. albopictus (Achee et al., 2019).  
 
1.5.7.2.2 Wolbachia 
Wolbachia is a genus of intracellular endosymbiotic bacteria that is estimated to naturally 
infect 60% of arthropod species and is vertically transmitted from the mother to progeny 
(Hilgenboecker et al., 2008). Wolbachia do not naturally infect Ae. aegypti species and the 
stable transinfection of the D. melanogaster-derived strain, wMel Wolbachia pipientis into Ae. 
aegypti has been shown to reduce both lifespan and vectorial capacity; suppressing the ability 
of mosquitoes to transmit DENV, CHIKV, YFV and ZIKV (Walker et al., 2011; van den Hurk et 
al., 2012; Aliota et al., 2016). Therefore, wMel Wolbachia-infected mosquitoes provide a 
means of population replacement. Mating between Wolbachia-infected male mosquitoes and 
non-infected females results in cytoplasmic incompatibility, whereby yielded eggs fail to 
develop (McMeniman et al., 2009). Regular releases of Wolbachia-infected male mosquitoes 
therefore may provide another method of population suppression, although further 
development is required to obtain a sustainable deployment strategy. The biocontrol initiative, 
the World Mosquito Program™ (www.eliminatedengue.com) is currently operating in 12 
countries worldwide, conducting controlled field releases of Wolbachia-infected Ae. aegypti to 
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assess the impact on mosquito-borne diseases and analyse the sustainability of this 
intervention over time (World Mosquito Program, 2019).  
 
1.5.7.2.3 CRISPR-Cas9 Gene drives 
Gene drives are transgenic constructs engineered to express a desired gene within an 
organism that is able to enhance its own representation in a sexually reproducing population, 
to ultimately invade target species populations (Leftwich et al., 2018). Current gene drive 
strategies incorporate the Clustered Regularly Interspaced Short Palindromic Repeats 
(CRISPR)-CRISPR-associated protein 9 (Cas9) gene editing system, whereby a transgenic 
construct is integrated into the mosquito host genome in a specific target sequence and 
functions by converting drive-heterozygotes into homozygotes during developmental stages 
(Gantz and Bier, 2015). The drive cassette expresses the Cas9 nuclease and a single guide 
RNA (sgRNA) to create a double-stranded break in the target sequence which can be repaired 
through homology-directed repair (HDR) to create a second copy of the gene construct (Gantz 
and Bier, 2015).  
 
This methodology can be applied to population replacement strategies to confer mosquito 
resistance to significant arboviruses or other pathogens, ultimately creating a resistant 
population (Achee et al., 2019). A recent proof-of-principle laboratory study has demonstrated 
the application of this approach, conferring Plasmodium falciparum resistance in Anopheles 
stephensi (Gantz et al., 2015). Although CRISPR-Cas9 gene drive approaches are not yet 
optimal to progress to field studies (Achee et al., 2019), deciphering the antiviral roles of the 
mosquito innate signalling pathways and their mechanisms of inhibition could potentially aid 
the design and development of mosquitoes incapable of transmitting DENV and other 
significant arboviruses, thereby reducing future outbreaks. 
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1.6 Aims and Objectives 
The overall aim of this M.Phil. project is to determine how DENV-2 antagonises the IMD 
pathway in Ae. aegypti. The main project aims are listed below in priority order, including the 
objectives for each. 
 
1) Identify the DENV-2 viral antagonist of the IMD pathway. 
• Optimise and perform a screen to identify the IMD immune antagonist encoded by 
DENV-2. Each DENV-2 protein will be expressed alone and in combination (e.g. 
NS2B/3 protease complex) in Aag2 cells prior to stimulation of IMD signalling by 
well-defined immune stimuli such as heat-inactivated Escherichia coli. Immune 
gene induction in the presence and absence of DENV-2 proteins will then be 
measured using previously validated RT-qPCR assays.  
• New and previously-developed plasmid-based tools created for the validation of 
identified IMD antagonist(s) will be tested. 
 
2) Generation of IMD and/or Toll pathway functional knockout Aag2 cell lines by CRISPR-
Cas9. 
• Aag2 cells are an Ae. aegypti cell line of embryonic origin that is widely used to 
study mosquito immune pathways and virus-host interactions. Our laboratory 
previously used CRISPR-Cas9 gene editing to create Aag2-derived cell lines 
lacking essential immune pathway genes to study the effects of immune pathway 
knockout on arbovirus replication. Therefore putative IMD and/or Toll pathway-
deficient cell lines must be characterised. Insertion/deletions (indels) will be 
determined to confirm that resulting phenotypes are not due to off-target effects.  
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3) Characterisation of Aag2 single cell clones. 
• Due to the phenotypic diversity of Aag2 cells, our laboratory generated a panel of 
Aag2-derived single cell clones to create a homogeneous background for CRISPR-
Cas9 gene editing experiments. The Aag2 clones have been assessed for a 
number of characteristics in relation to the parental Aag2 cell line, including 
immune function and susceptibility to arbovirus infection. Within this project, the 
phenotypic analyses of Aag2 single cell clones will be completed. The presence of 
viruses that are known to persistently infect Aag2 cells will be detected using 
reverse transcription- polymerase chain reaction (RT-PCR). The sex of the clonal 
cells and the parental Aag2 cell line will also be determined, using primers 
designed to amplify the splice variants of sex-dependent genes. Lastly the 
transfection efficiency of parental Aag2, Aag2-AF5 and Aag2-AF12 cell lines will 
be quantified to determine their suitability for molecular-based experiments. 
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2.1 Cells  
The Aag2 cell line was a kind gift of Prof. Raul Andino (University of California at San 
Francisco, CA USA).  Single cell clones (Aag2-AF1-12,14,15) were previously generated by 
Dr Kevin Maringer and Anthony Fredericks at the Icahn School of Medicine at Mount Sinai, 
New York, NY USA (Table 2.1). Aag2 Rel1A and Rel2 knockout cell lines were generated 
from the Aag2-AF5 cell clone by Dr Kevin Maringer and Anthony Fredericks (Fredericks et al., 
2019).  
 
Aag2 cells (including single cell clones and knockout cell lines) were maintained in Leibovitz’s 
15 media (L-15; Sigma-Aldrich, St. Louis, MO USA) supplemented with 10% or 20% heat-
inactivated (HI) BSE-free low endotoxin foetal bovine serum (FBS; GIBCO, Waltham, MA 
USA), 10% tryptose phosphate broth (Sigma-Aldrich), 20 mM L-glutamine (GIBCO), 1% non-
essential amino acids (GIBCO) and 100 U/ml penicillin-streptomycin (GIBCO), herein referred 
to as L-15/10% media, in a humidified incubator at 28°C without CO2. 
 
2.1.1 Cell passaging  
For routine passaging of confluent cells, supernatant was removed and cells scraped into L-
15/10% FBS (pre-warmed to 28°C). Cells were separated gently by pipetting and diluted 1:2 
to 1:4 into a fresh T75 flask (Corning, Corning, NY USA) with a total volume of 15 ml fresh 
media. Cells were passaged a maximum of twice per week, depending on growth rate and 
were discarded after 20 passages from our original laboratory stock. 
 
During experimental set-up, cell suspensions were seeded at 1 x 106 cells per well in 1 ml L-
15/10% FBS for 12-well plates or 1 x 105 cells/well in 100 µl L-15/10% FBS in 96-well plates.  
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Table 2.1 Cell lines. 
Cell Line Description sgRNA1 used 
(knockout cell lines) 
Aag2  Embryonic Ae. aegypti cell line (also referred to as parental Aag2 
cells) 
N/A 
Aag2-AF1 Single cell clone from parental Aag2 cell line N/A 
Aag2-AF2 Single cell clone from parental Aag2 cell line N/A 
Aag2-AF3 Single cell clone from parental Aag2 cell line N/A 
Aag2-AF4 Single cell clone from parental Aag2 cell line N/A 
Aag2-AF5 Single cell clone from parental Aag2 cell line N/A 
Aag2-AF6  Single cell clone from parental Aag2 cell line N/A 
Aag2-AF7 Single cell clone from parental Aag2 cell line N/A 
Aag2-AF8 Single cell clone from parental Aag2 cell line N/A 
Aag2-AF9  Single cell clone from parental Aag2 cell line N/A 
Aag2-AF10 Single cell clone from parental Aag2 cell line N/A 
Aag2-AF11 Single cell clone from parental Aag2 cell line N/A 
Aag2-AF12 Single cell clone from parental Aag2 cell line N/A 
Aag2-AF14 Single cell clone from parental Aag2 cell line N/A 
Aag2-AF15 Single cell clone from parental Aag2 cell line N/A 
Aag2-AF16 Putative Rel1A-/- cell line derived from Aag2-AF5 parental clone sgAF12 (Rel1A, exon 2) 
Aag2-AF25 Putative Rel1A-/- cell line derived from Aag2-AF5 parental clone sgAF12 (Rel1A, exon 2) 
Aag2-AF66 Putative Rel2-/- cell line derived from Aag2-AF5 parental clone sgAF18 (Rel2, exon 2) 
Aag2-AF69 Putative Rel2-/- cell line derived from Aag2-AF5 parental clone sgAF18 (Rel2, exon 2) 
Aag2-AF92 Putative Rel2-/- cell line derived from Aag2-AF5 parental clone sgAF19 (Rel2, exon 2) 
Aag2-AF251 Putative Rel1A-/-Rel2-/-  cell line derived from Aag2-AF5 parental 
clone 
sgAF12 (Rel1A, exon 2) 
Aag2-AF256 Putative Rel1A-/-Rel2-/-  cell line derived from Aag2-AF5 parental 
clone 
sgAF14 (Rel1A, exon 
3), sgAF19 (Rel2, exon 
2) 
1 Single guide RNA; sgRNA. 
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2.1.2 Cryopreservation  
Confluent T75 flasks of cells were resuspended in 10 ml L-15/20% FBS. 10 μl of 0.4% trypan 
blue stain was added to 10 μl cell suspension for 3-5 minutes at room temperature and viable 
cells counted using the Countess™ II cell counter (all ThermoFisher Scientific; Waltham, MA 
USA). Cells were pelleted at 1,300 RPM for 5 minutes at 4°C in a TX-400 swinging bucket 
rotor in a Heraeus™ Megafuge™ 16R Centrifuge (ThermoScientific) and resuspended in L-
15/20% FBS containing 10% dimethyl sulphoxide (DMSO; Corning) to give a cell density of 3 
x 106 viable cells/ml. 1 ml aliquots were frozen at -80°C in a CoolCell LX freezing container 
(Corning) for a minimum of 24 hours before transfer to liquid nitrogen for long-term storage.  
 
2.1.3 Cell resuscitation 
Thawed cells were added to 10 ml L-15/20% FBS and pelleted as in section 2.1.2. The pelleted 
cells were resuspended in 6 ml L-15/20% FBS and transferred to a T25 flask (Corning). Once 
confluent, the cells were passaged into a T75 flask in L-15/20% FBS and after reaching 70-
80% confluency the supernatant was removed and replaced with L-15/10% FBS. When 
confluent, the cells were passaged and maintained in L-15/10% FBS. 
 
2.2 Plasmids 
Strep-tagged DENV-2 protein-expression plasmids (Table 2.2) were kindly provided by Prof. 
Nevan Krogan (University of California, San Francisco, CA USA) (Shah et al., 2018). DENV-
2 (Strain 16681) genes (Kinney et al., 1997) were inserted into a pAc5.1 vector backbone 
containing a Actin5c Drosophila promoter, allowing high-level transient expression in insect 
systems, including mosquito cells. These plasmids also feature an ampicillin resistance 
marker and two C-terminal Strep-II tags for protein detection.  
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Other plasmids used in this project were cloned by inserting genes of interest into a pIEx-1 
backbone plasmid, kindly provided by Dr Doug Brackney (Colorado State University, Fort 
Collins, CO USA) (Scott et al., 2010). Gene transcription is driven by an hr5 enhancer and the 
IE1 immediate early promoter derived from Autographa californica nuclear polyhedrosis virus, 
allowing high-levels of transient expression insect cells. pIEx backbone also contains an 
ampicillin resistance marker.  
 
Plasmids with names beginning with “pKM” were created by Dr Kevin Maringer. Plasmids 
cloned in this project were sequenced by DBS Genomics (University of Durham, UK) or by 
using the Mix2Seq kit (Eurofins Genomics, Ebersberg, Germany) and analysed using 4Peaks 
software (A. Griekspoor & T. Groothius, mekentosj.com) before use in experiments. 
 
2.3 Primers 
All primers used in this project (Table 2.3) were manufactured by Sigma-Aldrich. 
 
In-Fusion® cloning primers were designed so that the extremities of the amplified insert contain 
15 bp overhangs complimentary to the digested vector, allowing orientation-specific insertion.  
 
Primers for CRISPR-Cas9 indel characterisation were designed using the Primer-Basic Local 
Alignment Search Tool (BLAST) (Ye et al., 2012) and were checked for specificity against the 
Ae. aegypti genome. Primer pairs with similar melting temperatures, GC content and low self-
complementarity scores were selected for synthesis. 
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Table 2.2. Plasmids. 
Plasmid name Alternative 
reference 
within 
thesis  
Encoded Protein Protein 
molecular 
weight 
(kDa) 
pAc-2xStrep(C) - Empty Strep-tag® cloning vector (C-terminal tag). - 
pAc-EGFP - Strep-tagged enhanced GFP. 30 
pAc-C - Strep-tagged DENV-2 C. 12 
pAc-CA - Strep-tagged DENV-2 C (+ transmembrane anchor). 12 
pAc-TMC-prM - Strep-tagged DENV-2 prM (+ transmembrane domain of C). 22 
pAc-TMM-E - Strep-tagged DENV-2 E (+ transmembrane domain of prM). 54 
pAc-NS1 - Strep-tagged DENV-2 NS1. 40 
pAc-NS2A - Strep-tagged DENV-2 NS2A. 22 
pAc-NS2B - Strep-tagged DENV-2 NS2B. 15 
pAc-NS3 - Strep-tagged DENV-2 NS3. 70 
pAc-NS2B/3 - Strep-tagged DENV-2 NS2B/3 protease. 70 
pAc-NS4A - Strep-tagged DENV-2 NS4A. 16 
pAc-NS4B - Strep-tagged DENV-2 NS4B. 27 
pAc-NS5 - Strep-tagged DENV-2 NS5. 105 
pAc-MCO-C - Mosquito codon optimised, Strep-tagged DENV-2 C. 12 
pAc-MCO-CA - Mosquito codon optimised, Strep-tagged DENV-2 C (+ 
transmembrane anchor). 
12 
pAc-MCO-TMC-
prM 
- Mosquito codon optimised, Strep-tagged DENV-2 prM (+ 
transmembrane domain of C). 
22 
pAc-MCO-
TMM-E 
- Mosquito codon optimised, Strep-tagged DENV-2 E (+ 
transmembrane domain of prM). 
54 
pAc-MCO-TMC-
prM-E 
- Mosquito codon optimised, Strep-tagged DENV-2 prM (+ 
transmembrane domain of C and E). 
80+58 
pAc-MCO-NS2A - Mosquito codon optimised, Strep-tagged DENV-2 NS2A. 22 
pAc-MCO-NS2B - Mosquito codon optimised, Strep-tagged DENV-2 NS2B. 15 
pAc-MCO-NS3 - Mosquito codon optimised, Strep-tagged DENV-2 NS3. 70 
pAc-MCO-
NS2B/3 
- Mosquito codon optimised, Strep-tagged DENV-2 NS2B/3. 70 
pAc-MCO-NS4A - Mosquito codon optimised, Strep-tagged DENV-2 NS4A. 16 
pAc-MCO-NS4B - Mosquito codon optimised, Strep-tagged DENV-2 NS4B. 27 
pAc-MCO-NS5 - Mosquito codon optimised, Strep-tagged DENV-2 NS5. 105 
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pIEx-EGFP-ub-
NS5 
- DENV-2 NS5 with an N-terminal EGFP tag and linker consisting of 
Homo sapiens ubiquitin. NS5 is also C-terminally Strep-tagged. 
132 
pIEx-1-EGFP - Enhanced GFP (Scott et al., 2010). 27 
pKM22 pIEx-
mCherry-
Rel2 
Ae. aegypti Rel2 gene (long isoform, Shin et al., [2002]. VectorBase 
ID AAEL007624) with N-terminal mCherry tag. 
140 
pKM3 pIEx-FLAG FLAG® tag only. 1 
pKM1  pIEx-IMD-
FLAG 
Ae. aegypti IMD gene (VectorBase ID AAEL010083) with C-terminal 
FLAG® tag. 
31 
pKM5  pIEx-FLAG-
Rel2(N) 
Ae. aegypti Rel2 gene (long isoform, Shin et al., [2002]. VectorBase 
ID AAEL007624) with N-terminal FLAG® tag. 
114 
pKM8 pIEx-
Rel2(C)-
FLAG 
Ae. aegypti Rel2 gene (long isoform VectorBase ID – AAEL007624) 
with C-terminal FLAG® tag. 
114 
pKM33  pIEx-
Rel2DIκB 
Ae. aegypti Rel2 gene (long isoform, Shin et al., [2002]. VectorBase 
ID AAEL007624) with its C terminal IκB domain deleted, based on 
Drosophila Relish data and prediction of caspase cleavage site 
(Stöven et al., 2003). Tagged with FLAG® at its N-terminus. 
64 
pLEW1  pIEx-EGFP-
MCO-NS4A 
MCO NS4A with N-terminal EGFP tag. 43 
pLEW2  pAc-
2xStrep(N) 
Empty Strep-tag® cloning vector (N-terminal tag). - 
pLEW3  pAc-MCO-
NS4A(N) 
MCO DENV-2 NS4A with N-terminal Strep-tag®. 16 
pKM20  pIEx-
EGFP(N) 
Empty EGFP cloning vector (N-terminal tag). 27 
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Table 2.3 Primers. 
Primer Set Sequence Amplicon 
Size (bp) 
Target/Use 
Cloning and sequencing primers (In-Fusion® cloning, section 2.4.4) 
prLEW14 F1 GCTGTACAAGAAGCTTTCGCTGACCTTGAACCTGATCA 415  MCO NS4A for 
pIEx-EGFP-NS4A 
cloning R2 TCACTTAGTGCTCGATTAACGTTGTTTCTCTGGTTCCGGAA 
prLEW16 F TTGGAGGACCAAGCTTGATGTCGCTGACCTTGAACCTG
ATCA 
419 MCO NS4A for 
pAc-MCO-NS4A(N) 
cloning R TGTTGATTCCGGAACCAGAGAAACAACGTTGATCGAGG
TCGACAGCG  
prLEW19 F GGGGTACCGAGCTCGGATCCACTAGTCCAGTGTGGTGG
AATTCGCCGCCATGTGGAGTCATCCACAATT 
N/A  1 of 3 overlapping 
primer sets for 
pAc-2xStrep(N) 
insert 
R AATTGTGGATGACTCCACATGGCGGCGAATTCCACCAC
ACTGGACTAGTGGATCCGAGCTCGGTACCCC    
prLEW20 F GAGTCATCCACAATTCGAAAAAGGTGGAGGTAGTGGAG
GTGGAAGTGGTGGAGGTAGTTGGAGTCATCCACAATTT
GAGAAACCACCACCAGAACTTCTTGGA 
N/A 2 of 3 overlapping 
primer sets for 
pAc-2xStrep(N) 
insert R TCCAAGAAGTTCTGGTGGTGGTTTCTCAAATTGTGGAT
GACTCCAACTACCTCCACCACTTCCACCTCCACTACCT
CCACCTTTTTCGAATTGTGGATGACTC 
prLEW21 F CCAGAACTTCTTGGAGGACCAAGCTTGCCCGGGCAGAT
CTCTCGAGGTCGACAGCGGAGACTTTAATGATAAGATC
CAGACATGATA 
N/A 3 of 3 overlapping 
primer sets for 
pAc-2xStrep(N) 
insert 
 
R TATCATGTCTGGATCTTATCATTAAAGTCTCCGCTGTC
GACCTCGAGAGATCTGCCCGGGCAAGCTTGGTCCTCCA
AGAAGTTCTGG 
prKM43 F GATAACCGCGTTGGTTTTA N/A Sequencing 
primers for pIEx-
backbone plasmids R CCAACTCCCATTGTTATTTCTATGCA 
prKM713 F TCATATCACTACCGTTTGAG N/A Sequencing 
primers for pAc-
backbone plasmids R TCACTGCATTCTAGTTGTGG 
Primers for CRISPR-Cas9 indel characterisation (CloneJET cloning, section 2.4.5) 
prLEW1 4  F CACATCCAGCGGACCAGTCA 2508 Rel1A, sgRNA site 
sgAF12 (exon 2). 
R TAGAATCGCGGCTGCAAAGC  
prLEW2 4 F CCCTTCCACCCACAAGCTCA 2691 Rel1A, sgRNA site 
sgAF12 (exon 2). 
R TCCGCATGTCCTTCGTCTGTT 
prLEW3 4 F GGCCTTCCGGTCCTTTACGA 2670 Rel1A, sgRNA site 
sgAF14 (exon 3). 
R TGACCGATGTCTTGCTGCGA 
prLEW4 4 F TGTGCTCCCCRCCRAAGCAC 2691 Rel1A, sgRNA site 
sgAF14 (exon 3). 
R GAGGGCCTAACGCAAGAGGA 
prLEW5 4 F CGCCTGCTCCGCGATCTAAA 2341 
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R CCCGTAAGGGCACTCTCTGT Rel2, sgRNA sites 
sgAF18 and sgAF19 
(exon 3). 
prLEW6 5 F GAGAACCCTGCCCCACCTAC 2602 Rel2, sgRNA sites 
sgAF18 and sgAF19 
(exon 2). R CCAATGTCACGTGAGAGGCAA  
prLEW7 4 F CAAGGATGGAACTACGAACATGCAA 2504 Rel1A, sgRNA site 
sgAF12 (exon 2). 
R CTGGGGATCGAAGAGTGGTTAGAAT 
prLEW8 4 F CCGCACGAATGTCAACAAAACAAAA 2581 Rel1A, sgRNA site 
sgAF12 (exon 2). 
R TAGTCTATCTAGTCAAGGACACCCGT 
prLEW9 5 F ACCTGTTTCACAAATTCGATGCCTT 2368 Rel1A, sgRNA site 
sgAF14 (exon 3). 
R GTTGTTGTACTGGCGGAAAGATCAG 
prLEW10 4 F CCTCAATGCTTTCCCGTTATGGTTT 2443 Rel1A, sgRNA site 
sgAF14 (exon 3). 
R GAAAATGAGGTCTTGGTGGAACTGG 
prLEW11 4 F TCATCTACGATTCACTCCCAAAATCCG 2613 Rel1A, sgRNA site 
sgAF12 (exon 2). 
R AAGACTCGAAGGTCCTAAAGTAAAGCC 
prLEW12 4 F ACAAAATTGAGTGAACGAARCACGG 2702 Rel1A, sgRNA site 
sgAF12 (exon 2). 
R ATCAGGCATATACAATGTTTTCCTCCC 
RT-qPCR primers (section 2.8) 
prKM143 F TGCACCGGGGCCATTAC 148 Defensin D 
(VectorBase ID: 
AAEL00387, L5). 
Used at 0.3 µM. 
R CAGGTGGCCCGTTTCAGG 
prKM163 F AGCTGTTCGCAATTGTGCTGT 143 Cecropin D 
(VectorBase ID: 
AAEL000598, L2). 
Used at 0.3 µM. 
R TACAACAACCGGGAGAGCCTT 
prKM173 F GAAGCTGGTCGGCTGAAGAA 88 Cecropin B 
(GenBank ID: 
XM_001648640). 
Used at 0.5 µM. 
R CAACGGGTAGTCCCTTCTGG 
prKM273 F CCACGATCCCGCACTCTGA 82 RpS7 (VectorBase 
ID: AAEL009496, 
L5). Used at 0.2 
µM. 
R TACGCTTGCCGACGACTTCA 
Primers for RT-PCR sex determination of Aag2 cells (section 2.9) 
dsx3 F GATACTGAAAGGCGCCGACG 530, 993, 
1434 6 
Doublesex splice 
variants. Salvemini 
et al., (2011). dsx5 R
 GCAGAATATGGGACTGGTGC 
fru1 F CGGCATTGAACGGCTATCC 
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1 Forward primer 
2 Reverse primer 
3 Primer set designed by Dr Kevin Maringer 
4 Primer set unsuccessfully amplified target sequence 
5 Primer set successfully amplified target sequence 
6 Primer set amplifies multiple splice variants 
 
 
 
 
 
fru3 R GTTCTCTCTGCAGCTCTCG  714, 
2013 6 
Fruitless. splice 
variants. Salvemini 
et al., (2013). 
fru1c F CAAGTGTCAGTAATATGTCC 813 Fruitless sex non-
specific control, 
used with fru3 R. 
Salvemini et al., 
(2013). 
Primers for RT-PCR detection of persistent viruses in Aag2 cells (section 2.9) 
prKM2543 F CATCAATTGATGAAGCCAGAGAAAG 878 PCLV L segment 
(GenBank ID: 
KU936057), nts 
1601-2478. 
R GTCTTTATGTTTTCTGTACAGCCATAAT 
prKM2563 F AATGCAAACTGTTCTTGCAGATTCTG 1000 PCLV M segment 
(GenBank ID: 
KU936056), nts 
1481-2480. 
R GTAGCTTAAAATCTGCGTCGTTAGT 
prKM2573 F ATTATAAATATTCAAACACCCCAGTTATAAG 880 PCLV S segment 
(GenBank ID: 
KU936055), nts 
161-1040. 
R TTCTGATCATTTAACATTCTCAGAGCTA 
prKM2583 F TCATCTTATGTTGCACATGGACGC 840 CFAV (GenBank ID: 
KU936054) NS1-
NS2A, nts 2561-
3400. 
R CACCCTCCGGAAATCCGATTG 
prKM2593 F TGCTTTCGAGGGACAAATCGG 469 RpS7 (VectorBase 
ID: AAEL009496, 
L3), housekeeping 
gene. 
R AATTCGAACGTAACGTCACGTCC 
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2.4 Molecular Biology 
2.4.1 Polymerase chain reaction 
To amplify target genes or sequences, PCR was conducted using either CloneAmp™ HiFi 
PCR Premix (Clontech; Kusatsu, Japan) or AccuPrime™ HF Taq PCR polymerase 
(ThermoFisher). Reaction components and thermocycling conditions for each system are 
detailed below. 
 
2.4.1.1 CloneAmp™ PCR 
CloneAmp PCR reactions were carried out using the following components: 
CloneAmp™ HiFi PCR Premix (2x; Clontech)   12.5 µl 
Forward primer (10 µM)       0.5 µl 
Reverse primer (10 µM)       0.5 µl 
Template                50.0 ng 
Distilled water             to 25.0 µl 
 
Thermocycling was performed in either the C1000 Touch™ Thermal Cycler (Bio-Rad, 
Hercules, CA USA) or the Veriti™ 96-Well Thermal Cycler (ThermoFisher Scientific) using the 
following conditions:  
initial denaturation  98°C for 10 seconds 
denaturation   98°C for 10 seconds 
annealing   59°C for 5 seconds  
elongation    72°C for 5 seconds/ 1 kb target 
final elongation  72°C for 10 seconds                  
holding   4°C  
x34 cycles        
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Gradient PCR experiments were conducted using a peqSTAR Thermal Cycler (peqLab; 
Radnor, PA USA), testing annealing temperatures from 51-65°C in 2°C increments. 
 
2.4.1.2 AccuPrime™ PCR 
AccuPrime™ PCR reactions were carried out using the following components: 
AccuPrimeTM PCR Buffer I (10x; ThermoFisher)  2.0 µl 
Forward primer (10 µM)     0.4 µl 
Reverse primer (10 µM)     0.4 µl 
cDNA (diluted 1:2 in Nuclease Free Water [QIAGEN]) 0.4 µl 
AccuPrimeTM HF Taq Pol (5 U/µl; ThermoFisher)  0.1 µl 
Distilled water       16.7 µl 
 
Thermocycling was performed in the C1000 Touch™ Thermal Cycler (Bio-Rad) using the 
following conditions:  
initial denaturation   94°C for 2 minutes  
denaturation   94°C for 30 seconds 
annealing   58°C for 30 seconds    x35 cycles        
elongation   68°C for 1 minute 
final elongation  68°C for 5 minutes 
holding   4°C.  
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2.4.2 Agarose gel electrophoresis 
PCR products or digested plasmids were analysed on a 1-2% (w/v) agarose gel (agarose, 
Tris-Borate-EDTA (TBE) buffer [90 mM Tris base / 9 M boric acid / 2 mM EDTA disodium salt 
/ distilled water], 0.003% (v/v) SYBR® Safe (ThermoFisher Scientific); chemical manufacturers 
listed in Appendix A). Prior to loading the samples, 5x loading dye (0.25% [w/v] bromophenol 
blue/ 0.25% [w/v] xylene cyanol FF/ 30% [v/v] glycerol/ distilled water) was added to each 
sample at the appropriate volume. Samples were resolved in TBE buffer at 100 V for the 
appropriate length of time, alongside a BenchTop 1 kb DNA marker (Promega; Madison, WI 
USA) for DNA size comparison.  
 
Agarose gels were visualised by ultraviolet (UV) transillumination on the Fusion FX imaging 
platform (Vilber Lourmat, Collégien, France) and if required, DNA bands were excised and 
purified by gel extraction using NucleoSpin® Gel and PCR Clean-up kit (Macherey-Nagel, 
Düren, Germany) or Zymoclean™ Gel DNA Recovery Kit (ZymoResearch; Irvine, CA USA) 
as per manufacturer’s instructions. 
 
 
2.4.3 Restriction enzyme digestion 
All restrictive enzyme digestions were performed using reagents from Promega following 
manufacturer’s instructions. Typically 2-3 µg plasmid DNA was added to a reaction mix 
containing the optimal reaction buffer (10x; Table 2.4), 2 units of desired enzyme per 1 µg of 
DNA, 1 mg/ml of bovine serum albumin (BSA) and distilled water. Reactions were incubated 
at room temperature overnight or 37°C for 1.5 hours before being purified by agarose gel 
electrophoresis and extraction (section 2.4.2). 
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2.4.4 In-Fusion® cloning 
Specific cloning conditions for each plasmid generated are stated in Table 2.4. DNA inserts 
and digested vectors were purified by agarose gel electrophoresis and extraction (section 
2.4.2) before use in In-Fusion® reactions. For the pAc-2xStrep(N) insert consisting of three 
overlapping primer sets (prLEW19, -20 and -21), the forward and reverse primers of each set 
were added together in equal volumes, boiled and allow to cool to room temperature to allow 
proper annealing. 
 
For each reaction, 150 ng of vector was added in a 1:2 molar ratio with the required insert(s), 
along with In-Fusion® enzyme and distilled water. Reactions were incubated at 50°C for 15 
minutes before being added to competent bacterial cells. 
 
 
 
 pIEx-EGFP-MCO-NS4A 1 pAc-2xStrep(N) 1 pAc-MCO-NS4A(N) 1 
Insert 
Preparation 
NS4A amplified from 
pAc-MCO-NS4A1 using 
prLEW14 primers2, 
containing 15 bp 
overhangs for insertion 
into digested pIEx-EGFP 
Insert sequence split over 
three primer sets 
(prLEW19, -20, and -21) 2, 
with 15 bp overlaps 
between sets and at 
extremities for insertion 
into digested pAc-EGFP 
NS4A amplified from 
pAc-MCO-NS4A1 using 
prLEW16 primers2, 
containing 15 bp 
overhangs for insertion 
into digested pAc-
2xStrep(N) 
Vector 
Backbone 
Preparation 
2 µg pIEx-EGFP 1 
digested using XhoI and 
HindIII, Buffer B 
3 µg pAc-EGFP 1 double 
digested to remove EGFP 
gene, using BamHI, Buffer 
E 
2 µg pAc-2xStrep(N)1 
digested using XhoI and 
HindIII, Buffer B 
In-Fusion® 
Reaction 
2:1 insert: vector molar 
ratio, 150 ng vector 
2:2:2:1 insert: vector 
molar ratio, 150 ng vector 
2:1 insert: vector molar 
ratio, 150 ng vector 
Sequence 
Confirmation 
Colony PCR and Sanger 
sequencing 
Sanger sequencing Colony PCR, Sanger 
sequencing 
Cloning 
Schematic 
Diagram 
Appendix B Appendix C Appendix D 
Table 2.4 Cloning details for plasmids generated by In-Fusion® cloning. 
 
1 Table 2.2 
2 Table 2.3 
 
  
 
 
62 
2.4.5 CloneJET® cloning 
Genomic DNA (gDNA) was extracted from Aag2 and Aag2 immune gene knockout cell stocks 
using the Quick-gDNA™ Miniprep Kit (ZymoResearch) as per manufacturer’s protocol. 
Specific regions within the Rel1A or Rel2 genes were amplified from gDNA by CloneAmp™ 
PCR (see section 2.4.1). PCR products were resolved, visualised and extracted as described 
in section 2.4.2. Purified PCR products were ligated into the pJET1.2/blunt cloning vector 
(CloneJET™ PCR Cloning Kit; ThermoFisher) following the manufacturer’s protocol, including 
the incubation step for 30 minutes at room temperature.   
 
2.5 Bacteria 
2.5.1 Bacterial transformation 
Fifty µl Stellar™ Competent Cells (Clontech) or DH5α™ Competent Cells (ThermoFisher 
Scientific) were thawed on ice and incubated with 1-10 ng plasmid DNA in the maximum of 5 
µl for 30 minutes. Cells were heat shocked at 42°C for 60 seconds (Stellar™) or 20 seconds 
(DH5α™) and then incubated on ice for 2 minutes. Four hundred and fifty µl pre-warmed Super 
Optimal broth with Catabolite repression (SOC) medium (Clontech) was added and incubated 
for one hour at 37°C with shaking at 220 RPM in a Cooling Shaking Incubator NB-205LF (N-
BIOTEK, Bucheon, South Korea). 100 µl of transformed cells were plated onto LB-agar plates 
containing 50 µg/ml ampicillin and incubated at 37°C for 17-20 hours. Individual colonies were 
picked for further culturing in 3 ml (small-scale plasmid preparation) or 150 ml (plasmid stock 
preparation) LB containing 50 µg/ml ampicillin, incubated at 37°C for 17-20 hours with shaking 
at 220 RPM. 
 
2.5.2 Colony PCR 
Bacterial colonies were screened for the desired insert by colony PCR. Colonies were placed 
in 11.5 µl of water in domed-cap PCR tubes, heated to 95°C for 5 minutes in a Veriti™ 96 Well 
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Thermal Cycler (ThermoFisher Scientific) and subsequently amplified using CloneAmp PCR 
mix with 0.5 µM of relevant primers. Thermocycling was performed as in section 2.4.1.1. PCR 
products were resolved and visualised as described in section 2.4.2. 
 
2.5.3 Bacterial glycerol stocks  
Six hundred µl of overnight bacterial culture was added to 400 µl sterile glycerol (Sigma Life 
Science) and stored at -80°C. For bacterial culturing from a bacterial glycerol stock, a scraping 
of bacteria was added to 150 ml LB containing 50 µg/ml ampicillin (Sigma-Aldrich) and 
incubated at 37°C for 17-20 hours. 
 
2.5.4 Plasmid preparation 
Small-scale plasmid preparations were prepared from 3 ml overnight bacterial cultures using 
Zyppy™ Plasmid MiniPrep Kit (ZymoResearch) as per manufacturer’s instructions. 
 
Plasmid stocks were prepared from 150 ml overnight bacterial cultures using the QIAfilter 
Plasmid Maxi kit (QIAGEN, Hilden, Germany). Cells were pelleted at 3,660 x g for 20 minutes 
at 4°C using a Windshield 43124-708 BS440 swinging bucket rotor in a Mistral 3000i 
centrifuge (MSE, East Sussex, UK), resuspended in 10 ml P1 resuspension buffer containing 
RNase A and LyseBlue® and lysed in 10 ml of lysis buffer P2 at room temperature for 5 
minutes. The reaction was then neutralised with 10 ml Buffer P3. The lysate was incubated 
for 10 minutes in a QIAfilter cartridge to allow the white precipitate containing proteins and 
genomic DNA to rise to the top of the column. The lysate was filtered through the cartridge 
matrix and allowed to pass through a QIAGEN-tip (pre-equilibrated with buffer QBT) by gravity 
flow. The QIAGEN-tip was washed twice with ethanol-based wash buffer QC and DNA eluted 
into a 50 ml collection tube using 15 ml buffer QF. Eluted DNA was precipitated by addition of 
10.5 ml room-temperature isopropanol (Sigma-Aldrich) and pelleted at 3220 x g for 30 minutes 
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at 4°C using a swing-bucket A-4-81 rotor in an Eppendorf® Centrifuge 5810R (Eppendorf, 
Hamburg, Germany). The supernatant was decanted and the DNA pellet washed with 5 ml 
room temperature 70% ethanol (ThermoFisher Scientific). DNA was re-pelleted at 3220 x g 
for 10 minutes at 4°C. The supernatant was removed and the DNA pellet was air-dried for 10 
minutes before dissolving in 100 µl Buffer TBE or Zyppy™ Elution Buffer (ZymoResearch).  
 
DNA concentration and quality were determined by spectrophotometry using a NanoDrop™ 
2000 (ThermoFisher) and plasmid stocks were diluted to 1 µg/µl before storage at -20°C. 
 
2.5.5 Heat inactivated bacterial stock production 
Heat-inactivated (HI) E. coli stocks for use as an immune stimulant were prepared from 
DH5α™ Competent Cells (ThermoFisher Scientific). Fifty µl of cells were added to 150 ml LB 
without antibiotics and incubated at 37°C with shaking at 220 RPM for 20 hours in a Cooling 
Shaking Incubator NB-205LF (N-BIOTEK). Two hundred µl of sample was taken for bacterial 
titration (section 2.5.2) and the remainder pelleted at 3,660 x g for 20 minutes at 4°C using a 
Windshield 43124-708 BS440 swinging bucket rotor in a Mistral 3000i centrifuge (MSE). The 
supernatant was discarded and the pellet was frozen at -80°C. After titre determination the 
pellet was diluted in phosphate buffered saline (PBS; GIBCO) to a concentration of 1 x 1010 
CFU/ml and heat inactivated at 65°C for two hours. Heat inactivation of the culture was 
confirmed by lack of grown in LB medium without antibiotics incubated at 37°C with shaking 
at 220 RPM for 24 hours. One ml aliquots were prepared and stored at -80°C for long-term 
storage. 
 
2.5.6 Bacterial titration 
Six-well plates of LB agar were prepared by adding 2 ml sterile molten LB agar without 
antibiotic to each well, left to solidify at room temperature and stored at 4°C. Fifty µl cells were 
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added to 450 µl sterile PBS and a 10-fold dilution series performed in duplicate with dilutions 
ranging from 10-1 to 10-8. One hundred µl of each dilution were spread on a separate well of 
an LB agar plate, left to dry at room temperature and incubated at 37°C for 17-20 hours. 
Bacterial colonies were counted in wells containing 20-100 colonies to determine the 
concentration (CFU/ml) of bacteria in the culture.  
 
2.6 Transient Transfection 
Three µg of pAc-backbone plasmid or 300 ng of pIEx-backbone plasmid was complexed with 
2 µl TransIT®-Insect transfection reagent (Mirus, Madison, WI USA) in 100 µl serum-free L-15 
media for 30 minutes at room temperature as per manufacturer’s protocol. Transfection mixes 
were added to 12-well plates (ThermoFisher) before adding 1 x 106 viable Aag2 cells in 1 ml 
L-15/10% FBS and incubated at 28˚C.  
 
For RT-qPCR experiments, transfections were performed in 96-well plates (ThermoFisher) as 
described above but with all reagents and cell suspension volume scaled-down 10-fold. 
 
2.7 Immunoblotting 
2.7.1 Lysate preparation 
Cells were transfected in 12-well plates as described in section 2.6.  In experiments involving 
proteasomal inhibition, 20 µM MG-132 (Sigma-Aldrich) was added to wells 18 hours prior to 
harvest unless otherwise stated.  
 
At 72 hours post-transfection, cells were lysed directly in 2x Sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE) sample buffer or 2x disruption buffer (DB) 
(Table 2.5), except in experiments when floating cells were visible, upon which 
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scraped into the covering media, placed into 0.5 ml microcentrifuge tubes, pelleted by 
centrifugation at 10,000 RPM for 5 minutes in a 2073 fixed angle rotor (Hettich Zentrifugen, 
Tuttlingen, Germany) in an M-24 centrifuge (Boeco; Hamburg, Germany) before lysing in 100 
µl 2x disruption buffer. Lysates were sonicated three times for 10 seconds unless otherwise 
stated and clarified by centrifugation as above for 1 minute. Where specified, for DNase 
treatment, lysates were incubated with 250 units Benzonase (Sigma-Aldrich) at 4°C for 20 
minutes on a tube rotator. Samples were stored at -20°C. 
 
 
Table 2.5 Immunoblotting buffers and solutions.  
1 Reagent manufacturers are listed in Appendix A 
2 Buffer was made with or without benzonase nuclease (Sigma-Aldrich; 250 units/ml). 
3 One tablet of protease inhibitors (cOmplete ULTRA Tablet Mini, EDTA-Free; Roche) was dissolved 
  in 10 ml RIPA buffer for harvesting 
 
Solution Composition1 
2x SDS-PAGE Sample Buffer 2 Tris pH7 (100 mM), 4% SDS (w/v), 10% beta-mercaptoethanol 
(v/v), 20% glycerol (v/v), 0.2% bromophenol blue (w/v), in 
distilled water 
2x Disruption Buffer 2 Urea (6 M), beta-mercaptoethanol (2 M), 4% SDS (w/v), 
bromophenol blue in distilled water 
RIPA Buffer 2, 3 Tris pH 7.5 (50 mM), NaCl (150 mM), 0.1% SDS (w/v), 1% sodium 
deoxycholate (w/v), 0.2% Triton™ X-100 (v/v), in distilled water  
1x SDS-PAGE Running Buffer Tris base (25.0 mM), glycine (192 mM), SDS (3.5 mM) in distilled 
water 
1x Transfer Buffer Tris base (25 mM), glycine (192 mM), 20% methanol (v/v), in 
distilled water 
TBS-Tween® 20 (TBS-T; wash 
buffer) 
Tris base (46 mM), Tris HCl (154 mM), NaCl (1.4 M), 1% Tween® 
20 (v/v) in distilled water (pH 7.6) 
5% milk in TBS-T (Blocking 
buffer) 
5% dried skimmed milk (w/v) in TBS-T  
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For lysis in radioimmunoprecipitation assay (RIPA) buffer (Table 2.5), cells were scraped into 
the covering media, pelleted as above and 100 µl RIPA buffer added with tubes kept on ice 
for 20 minutes. Insoluble material was pelleted by centrifugation at 12,000 RPM using a 
75003424 rotor in a Heraeus Fresco 21 Centrifuge (both ThermoScientific) at 4°C for 30 
minutes. Soluble material was transferred to a fresh 0.5 ml microcentrifuge tube and stored at 
-20°C. 
 
2.7.2 SDS-PAGE 
Cell lysates were denatured at 95°C for 5 minutes, unless otherwise stated. Samples were 
loaded onto 4-20% Mini-PROTEAN® precast gels (Bio-Rad) and proteins separated by sodium 
dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) at 120 V for 1 hour 15 
minutes in SDS-PAGE running buffer (Table 2.5).   
 
2.7.3 Protein transfer and immunoblotting 
Wet transfer was performed in transfer buffer (Table 2.4) at 400 mA for 1.5 hours onto an 
Immobilon®-FL Polyvinylidene Fluoride (PDVF) membrane (Merck Millipore, Burlington, MA 
USA), pre-activated in methanol. Membranes were blocked for one hour in blocking buffer 
(Table 2.5) and incubated overnight at 4°C with primary antibody (Table 2.6). Membranes 
were washed three times for 10 minutes in wash buffer (Table 2.5), incubated for one hour at 
room temperature with secondary antibody (Table 2.6) and washed as above.  
 
Membranes incubated with near-infrared (NIR) fluorophore-conjugated secondary antibodies 
were scanned on an Odyssey® CLx NIR scanner (LI-COR Biosciences, Lincoln, NE USA) and 
analysed using Image Studio™ software (LI-COR Biosciences). Membranes incubated with 
horseradish peroxidase (HRP)-conjugated secondary antibodies were incubated in 
SuperSignal™ West Pico Chemiluminescent Substrate (ThermoFisher) or Immobilon® 
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Western Chemiluminescent HRP Substrate (Merck Millipore) for 3 minutes before enhanced 
chemiluminescence (ECL) signal detection on either a Fusion FX imaging platform (Vilber 
Lourmat) or exposure to FUJIFILM Super RX Film (FUJIFILM, Tokyo, Japan). Film was 
developed manually using Polycon Manual X-ray Developer and Amfix Manual X-ray Fixer 
(both 20% [v/v] in water; Champion Photochemistry, Brampton, ON Canada). 
 
2.8 RT-qPCR 
For IMD signalling experiments, cells were transfected with the relevant plasmid (section 2.6) 
for 48 hours. The covering media was then removed and 1000 CFU/cell HI E. coli in 1 ml L- 
 
 
Table 2.6 Immunoblotting antibodies.  
1 Dilutions were empirically optimised. 
Antibodies (diluted in blocking buffer) Dilution1 (unless 
otherwise stated) 
Source 
Primary  Rabbit anti-human alpha tubulin, 
monoclonal  
1:2000 AbCam, Cambridge, UK 
(Cat# ab52866) 
Mouse anti-Strep-II, monoclonal  1:2000 QIAGEN (Cat# 34850) 
Mouse anti-FLAG®, monoclonal 1:5000 Sigma (Cat# F3165) 
Secondary 
 
Goat anti-mouse IRDye® 800CW, 
polyclonal  
1:20000 LI-COR Biosciences 
(Cat# 925-32210) 
Goat anti-rabbit IRDye® 680RD, 
polyclonal 
1:20000 LI-COR Biosciences 
(Cat# 925-68071) 
Goat anti-mouse HRP, polyclonal 1:10000 Dako, Agilent 
Technologies (Santa 
Clara CA USA; Cat# 
P044701-2) 
Goat anti-rabbit HRP, polyclonal  1:10000 Dako, Agilent 
Technologies (Cat# 
P044801-2) 
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15/10% FBS was added to relevant wells. L-15/10% FBS lacking bacteria was added to 
negative control wells. Plates were then incubated at 28°C for a further 24 hours. All conditions 
were performed in triplicate.  
 
Cells were harvested in 300 µl RNA Lysis Buffer (ZymoResearch) and RNA isolated using the 
Quick-RNA™ MiniPrep kit (ZymoResearch) as per manufacturer’s protocol. Fifty-200 ng RNA 
(depending on RNA yield) was reverse transcribed into complementary DNA (cDNA) using 
the iScript™ cDNA Synthesis Kit (Bio-Rad) in a total reaction volume of 10 µl, as per 
manufacturer’s protocol. 
 
qPCR amplification was performed using gene-specific primers (Sigma-Aldrich; Table 2.3) and 
the HOT FIREPol® EvaGreen® qPCR Mix Plus without ROX™ (Solis BioDyne, Tartu, Estonia) 
as per manufacturer’s instructions, as follows: 
 
HOT FIREPol® EvaGreen® qPCR Mix (5x)     2.0 µl 
Forward primer (10 µM)       (Table 2.6) 
Reverse primer (10 µM)       (Table 2.6) 
cDNA (diluted 1:5 in Nuclease-Free Water [Qiagen])   5.0 µl 
Distilled water         to 10.0 µl 
 
Thermocycling was performed using the Quant Studio® 7 Flex (ThermoFisher Scientific) using 
the following conditions: 95°C for 15 minutes, 40 cycles of 95°C for 15 seconds and 60°C for 
20 seconds, followed by a melt curve analysis. Data were analysed by the Livak method 
(∆∆CT; Livak and Schmittgen., 2001) using Quant Studio® Real-Time PCR software 
(ThermoFisher Scientific).  
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2.9 RT-PCR  
Total cellular RNA was isolated from 1.5 x 106 parental Aag2 cells and single-cell clones using 
the Quick-RNA™ MiniPrep kit (ZymoResearch) as per the manufacturer’s protocol. The 
concentration and quality of the RNA was determined by spectrophotometry using a 
NanoDrop™ 2000 (ThermoFisher) and samples were stored at -80°C. 
 
Reverse transcription was performed using the Maxima™ H Minus First Strand cDNA 
Synthesis Kit (ThermoFisher) using 100 ng of RNA with gene-specific (Sigma-Aldrich; Table 
2.3) or random hexamer primers as specified.  
 
For sex determination RT-PCR, targets were amplified with CloneAmp™ PCR mix as 
described in section 2.4.1.1 using gene specific primers (Table 2.3), before being analysed by 
agarose gel electrophoresis (section 2.4.2) 
 
RT-PCR experiments to detect PCLV, CFAV and RpS7, targets were amplified with 
AccuPrime™ HF Taq polymerase (ThermoFisher) as described in section 2.4.1.2, using the 
relevant primers listed in Table 2.3. PCR samples were resolved and visualised by agarose 
gel electrophoresis as in section 2.4.2. 
 
2.10 Fluorescence microscopy 
Cells were seeded and transfected in 12-well plates as described in sections 2.1.1 and 2.6, 
incubated at 28°C. At the relevant time post-transfection, live cells were viewed and imaged 
using either an EVOS® FL fluorescence microscope (ThermoFisher Scientific) or an Axiovert® 
S100TV fluorescent microscope (Zeiss, Oberkochen, Germany).  
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In transfection efficiency experiments, EGFP-positive cells were manually counted from 
captured images on ImageJ software (NIH, Bethesda, MA USA; Schneider et al., 2012).  
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CHAPTER 3 
Characterisation of Aag2 Single Cell Clones 
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3.1 Chapter Introduction  
 
The study of vector-virus interactions using in vivo approaches requires a wide range of skills 
in handling and rearing large mosquito populations while working with viruses. Having the 
appropriate containment facilities for working with both virus and vector at high containment 
is therefore essential, which limits the number of research groups able to conduct this type of 
work. Therefore a more feasible and readily accessible method for this type of research is 
through the in vitro use of mosquito tissue culture cell lines, which have become indispensable 
tools in arbovirus-based research. Such cell lines have been used extensively to study virus-
host interactions and mosquito immunology, as well as to isolate and propagate arboviruses.  
 
Interest in mosquito-based research has increased over the years due to the (re-)emergence 
of DENV, CHIKV (Sam et al., 2015), YFV (Douam and Ploss, 2018) and ZIKV (Gatherer and 
Kohl, 2016). Ae. aegypti is the major vector for all of these significant human arboviral 
diseases yet despite the demand, as Ae. aegypti is not a model organism, the molecular tools 
and cell lines available for use are still extremely limited.  
 
The first published attempts to develop mosquito cell culture systems began in the 1930s, with 
the first major finding from Trager (1938) showing that surviving mosquito tissues supported 
the proliferation of western equine encephalitis virus, therefore highlighting that tissue culture-
based experiments would be of advantage as an alternative to studying virus proliferation in 
vivo. Over the following 30 years there were multiple attempts to grow and maintain mosquito 
cells in culture (Trager, 1938; Gavrilov and Cowez, 1941; Ball, 1954; Beckel, 1956; Peleg and 
Trager, 1963; Trager, 1965) but in the majority of cases growth of mosquito tissue was 
unsuccessful. Finally in 1966, Grace established the first mosquito larval cell line, Ae. aegypti 
(L) that could be successfully maintained in tissue culture. This was followed shortly by the 
creation of other Ae. aegypti cell cultures such as Peleg’s embryonic cell line in 1968, now 
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referred to as Aag2 cells (Lan and Fallon, 1990), the ATC-10 larval cell line (Singh, 1969), the 
embryonic A20/Aa20 cell line (Pudney et al., 1979) and the RML-12 larval cell line (Kuno et 
al., 1983), although there is more recent evidence that suggest RML-12 cells were derived 
from Ae. albopictus (Voronin et al., 2010). Over the years following their establishment, 
multiple studies confirmed that these cell lines permitted the growth of numerous arboviruses 
(Peleg, 1968; Peleg, 1969; Řeháček, 1968; Singh and Paul, 1968a; Singh and Paul, 1968b), 
validating their value for in vitro arbovirus research. 
 
After five decades, these cell lines are still used for the majority of Ae. aegypti immune-based 
studies (Table 3.1). Currently, only ATC-10 is commercially available from the American Type 
Culture Collection (ATCC) and the European Collection of Authenticated Cell Cultures 
(ECACC), with the other cell lines being distributed from the laboratories that use them. 
Despite being established in the 1960-1970s, these cell lines remain poorly defined. Multiple 
studies have now shown that commonly used Ae. aegypti, Ae. albopictus and other insect cell 
lines harbour multiple persistent insect-specific viruses (Bell-Sakyi and Attoui, 2013; Bell-
Sakyi and Attoui, 2016; Maringer et al., 2017; Stollar and Thomas, 1975; Wu et al., 2010, 
Weger-Lucarelli et al., 2018) which may impact experiments conducted in these cell culture 
systems and the conclusions drawn from data obtained. 
 
The majority of the work in our laboratory involves Aag2 cells. Although this cell line was first 
established in the 1960s, it was only in 2012 when a study by Barletta et al. demonstrated that 
this cell line is immunocompetent with functioning Toll, IMD, and JAK STAT pathways as well 
as RNAi (Scott et al., 2010) and that the elicited immune responses resemble those described 
for mosquitoes in vivo. Previous karyotype analyses determined that Aag2 cells contain three  
pairs of chromosomes, although an additional chromosome fragment has been observed in 
metaphase spreads in a low percentage of cells (Lan and Fallon, 1990). Therefore this cell 
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line is a useful tool for mosquito immunology-focused research, and with new and rapidly-
evolving gene editing technologies such as CRISPR-Cas9 gene editing, the genome can be 
precisely edited to study immune function in greater detail.    
 
3.1.1 Previous Work 
The Aag2 cell line (referred to in this section as the ‘parental Aag2 cell line’) was generated 
by homogenising pools of non-uniformly developed embryos from Ae. aegypti eggs, therefore 
the cell line is not homogeneous (Peleg, 1968). For the purposes of creating a homogeneous 
background for CRISPR-Cas9 gene editing pipelines, Anthony Fredericks (Icahn School of 
Medicine at Mount Sinai) previously used flow cytometry to generate a panel of 14 single cell 
Cell Line Origin Commercial 
availability 
Reference Notes 
Aedes 
aegypti L. 
Larval No Grace 
(1966) 
- 
Aag2 Embryonic No Peleg 
(1968) 
Later adapted by Lan and 
Fallon (1990) 
ATC-10  
(CCL-125) 
Larval ATCC, ECACC Singh 
(1967) 
- 
RML-12 Larval No Kuno 
(1983) 1 
Initially described in studies as 
an Ae. aegypti cell line. Two 
genes of mitochondrial DNA 
have now linked RML-12 to Ae. 
albopictus (Voronin et al., 
2010). 
Created by Bhat, U.K.M. 
1Earliest reference to cell line. 
A20/ Aa20 Embryonic No Pudney et 
al., 1979 
- 
Table 3.1 Summary of commonly used Ae. aegypti cell lines. 
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Aag2 clones (Aag2-AF1-12, -AF14, -AF15; Figure 3.1). These clones have been assessed for 
a number of characteristics, including immune function and susceptibility to a number of 
arboviruses (Fredericks et al., 2019). Based on the phenotypic similarity to the parental Aag2 
cell line, the Aag2-AF5 clone was selected for further work including CRISPR-Cas9 gene 
knockout of essential immune pathway genes. 
 
This chapter continued the phenotypic analyses of the panel of generated single cell clones 
to further characterise them in relation to their parental Aag2 cell line. The presence and 
replication of reported persistent viruses in the Aag2 cell lines was determined by sense- 
 
 
 
 
 
Figure 3.1. Workflow for the generation of Aag2 single cell clones and CRISPR-Cas9 
experiments. Diagram adapted from Anthony Fredericks. 
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specific and non-sense-specific RT-PCR. The sex of the parental Aag2 cell line was 
investigated using published primers for RT-PCR to amplify sex-specific splice products. 
Lastly, the transfection efficiency of parental Aag2 and a subset of clonal cell lines of interest 
was determined by fluorescence microscopy. Some of the work described in this chapter 
contributed to a manuscript now deposited on BioRxiv (Fredericks et al., 2019) which will be 
highlighted in the figure legends. 
 
3.2 Presence of PCLV and CFAV in Aag2 Single Cell Clones 
 
The Aag2 cell line has previously been shown to be persistently infected with cell fusing agent 
virus (CFAV), the first described insect-specific flavivirus, isolated from cells by Stollar and 
Thomas (1975) and later in natural mosquito populations (Cook et al., 2006; Hoshino et al., 
2009; Espinoza-Gómez et al., 2011; Yamanaka et al., 2013). Furthermore, Aag2 cells have 
recently been shown by our group to be persistently infected with Phasi Charoen-like virus 
(PCLV) (Maringer et al., 2017), a recently discovered insect-specific bunyavirus (Chandler et 
al., 2014; Maringer et al., 2017) also found in wild populations (Zhang et al., 2018). 
 
Whether these viruses are present in our single cell clones is unknown. To address this, an 
RT-PCR assay was previously designed to amplify target sequences within each of the three 
negative-sense RNA genome segments of PCLV (small [S], medium [M] and large [L]) and 
was performed on the panel of single cell clones and parental Aag2 cells. Amplification of 
target sequences within the single-stranded positive- sense genome of CFAV was also 
amplified. Amplification of cellular 40S ribosomal protein S7 (RpS7) mRNA served as an input 
template control. Primers and target sequences amplified are stated in Table 2.3. Here, the 
experiment has been repeated to verify the previous findings (data not shown). 
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All three PCLV genome segments were detected in the majority of cell clones, suggesting that 
they are persistently infected with PCLV (Figure 3.2a). However, L segment was not detected 
in Aag2-AF1 and Aag2-AF4 clones while no M segment was detected in the Aag2-AF5 clone. 
The presence of two of the three segments suggests infection and the lack of the other 
segments may therefore be an RT-PCR sensitivity limitation. This could also be the case for 
Aag2-AF10 and Aag2-AF12 which lacked all PCLV segment amplicons, although this could 
also indicate lack of persistent infection. CFAV-specific PCR detected the viral product in all 
single cell clones (Figure 3.2a) confirming that all cell lines are persistently infected. The RpS7 
control was detected in all samples. 
 
In an attempt to increase the sensitivity of the reaction, both positive- and negative-sense-
specific reverse transcription reactions using the same PCLV M segment primers were 
performed in the Aag2-AF1, Aag2-AF4, Aag2-AF5, Aag2-AF10 and Aag2-AF12 clones, which 
previously lacked the segment (Figure 3.2a). The viral genomic product was observed in all 
of the single cell clones (Figure 3.2b), with Aag2-AF4 and Aag2-AF12 detectable at much 
lower levels than Aag2-AF1, Aag2-AF5, and Aag2-AF10. With the exception of the Aag2-AF12 
clone, the antigenome was detected for all clones, indicating that PCLV is present and actively 
replicating in these clones. Although the presence of the genomic product in Aag2-AF12 cells 
indicates infection, it cannot be concluded that the virus is actively replicating due to the 
absence of detectable replicative intermediate. 
 
Positive- and negative-sense-specific reverse transcription reactions for all PCLV segments 
were performed to test if this method allows the detection of the remainder of the PCLV 
segments in the Aag2-AF10 and Aag2-AF12 clones where no PCLV amplicons were initially 
observed (Figure 3.2a), as well as the parental Aag2 cells. RpS7 cDNA was synthesised using 
random hexamers as before. Consistent with data presented in Figure 3.2a, both positive- and 
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 (a) 
 
 
 
 
 
 
 
(b) 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2. Detection of PCLV and CFAV in Aag2 single cell clones. (a) RT-PCR detection of 
PCLV L (878 bp), M (1000 bp) and S segments (880 bp), CFAV (840 bp), and RpS7 (469 bp) in 
parental Aag2 cells and single-cell clones Aag2-AF1 to Aag2-AF15. These data contributed to 
Fredericks et al., (2019). (b) PCLV M segment RNA sense-specific RT-PCR for a subset of clones 
that lacked detectable products in (a). The 1.5 kb band was determined to be a non-specific Ae. 
aegypti sequence by Sanger sequencing.  
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negative-sense amplicons for all PCLV segments were detected in parental Aag2 cells, 
confirming persistent infection with PCLV (Figure 3.3). Genomic and antigenomic products 
were amplified for PCLV M segment (Figure 3.3) as previously shown for Aag2-AF10 cells 
(Figure 3.2b), however no amplicons were detected for the L or S segment. The presence of 
the M segment antigenome suggests that there may be active replication and that the L and 
S segments may be present at levels below the limit of detection. No PCLV-specific products 
were amplified for any segment in the Aag2-AF12 clone (Figure 3.3), including the M segment  
for which the genomic product had been previously observed in one experiment only 
(Figure3.2b). The detection of a genomic product for the PCLV M segment is therefore 
inconsistent in Aag2-AF12 cells and with the lack of detection of any other PCLV amplicons, 
it cannot be concluded that there is active replication but as previously suggested, this may 
be due to the detection limits of this assay. 
 
3.3 Sex Determination of the Parental Aag2 Cell Line 
As parental Aag2 cells were generated from a pool of embryos (Peleg, 1966), it is possible 
that the cell line contains cells from a mixture of both male and female individuals. Sex may 
be of interest to cell lines used for vector studies as female cells would be of greater biological 
relevance given that only female mosquitoes transmit disease to humans through blood 
feeding. Therefore, if the parental Aag2 cell line consists of a mix of male and female cells, it 
would be useful to generate clones consisting of only male or female cells for comparison 
purposes. Mosquitoes do not have sex chromosomes but instead have their sex determined 
by a male determining factor located within the M locus (Hall et al., 2015). It was discovered 
that Nix, a gene involved in the splicing of two regulators of sexual differentiation doublesex 
(dsx) and fruitless (fru) functions as an M factor in Ae. aegypti (Hall et al., 2015). Therefore, 
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Figure 3.3. Detection of PCLV and CFAV in Aag2-AF10, Aag2-AF12 and Aag2 parental cells 
using PCLV-specific RT primers. Sense-specific RT-PCR detection of PCLV L (878 bp), M (1000 
bp) and S segments (880 bp) and RpS7 (469 bp) for a subset of clones that lacked detectable 
products for all PCLV segments, Aag2-AF10 and Aag2-AF12, as well as the parental Aag2 cell line. 
Black arrowheads represent the correct size of the desired products; the red arrowhead represents 
a non-specific product amplified using PCLV M segment primers which was determined to be a non-
specific Ae. aegypti sequence by Sanger sequencing. These data contributed to Fredericks et al., 
(2019). 
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to determine the sex of the parental Aag2 cell line, dsx and fru were targeted for amplification 
based on sex identification assays (workflow shown in Figure 3.4) previously designed by 
Salvemini et al., (2011 and 2013) (Figure 3.5a-d).  
 
A study by Salvemini et al., (2013) using an RT-PCR assay to detect the sex-dependent splice 
variants of fru showed that a 0.7 kb product was amplified in adult males and a 2.0 kb product 
in adult females (Figure 3.5a). Although a sex-independent fru mRNA was expressed from 
embryonic stages through to male and female adult stage (Figure 3.5b), sex-dependent fru 
splice variant expression did not begin until late larval stage in a mixed sex population. This 
indicates that fru cannot be used for sex determination in the embryonic or early larval stages. 
No sex-dependent fru product was amplified from parental Aag2 mRNA, even though the sex-
independent control was successfully amplified (Figure 3.5e). Temperature gradient PCRs 
were also conducted to optimise the reaction to observe if any of the sex-specific products 
were amplified under different annealing temperatures, however this did not amplify any 
additional products (data not shown).  These results indicate that Aag2 cells retain their 
embryonic characteristics and that the fru RT-PCR assay is therefore not able to determine 
the sex of Aag2 cells. 
 
In a separate study designed to identify sex-dependent dsx transcripts by RT-PCR, Salvemini 
et al., (2011) showed that 1.0 kb and 1.5 kb products were amplified from adult females and 
a 0.5 kb product from adult males (Figure 3.5c).  In mixed-sex populations, the 0.5 kb and 1.0 
kb amplicons were also observed from the earliest embryonic stage (Figure 3.5d). Using this 
assay, amplification of dsx in the parental Aag2 cell line resulted in the female-specific 1.0 kb 
product (Figure 3.5e). The adult female-specific 1.5 kb product and the male-specific 0.5 kb 
product were not observed (Figure 3.5e), including when using different annealing 
temperatures (data not shown). The data therefore suggests that Aag2 cells may be female  
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Figure 3.4 Workflow for the sex determination of Aag2 cells by RT-PCR. RT-PCR workflow and 
schematic of the Ae. aegypti (a) dsx and (b) fru gene and splice variant transcripts. Red arrows 
indicate primer binding locations within the gene and transcripts. Images adapted from Salvemini et 
al., (2011) and (2013). 
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(d) 
Figure 3.5. Sex determination of Aag2 cells by doublesex and fruitless amplification by RT-
PCR. (a,b) Data from Salvemini et al., (2013). Expression profile of sex-dependent fru splice 
variants using fru1/fru3 primers, and sex-independent fru mRNA control using fru1c/fru3 primers in 
Ae. aegypti.   (c,d) Data from Salvemini et al., (2011). Expression profile of sex-dependent dsx 
using dsx3/dsx5 primers in Ae. aegypti. (e) RT-PCR to detect dsx and fru in parental Aag2 cells, 
including the sex-independent control for fru. E = embryo (E1, 2, 3, 4, early to late stages); L12 = 
early larvae; L34 = late larvae; P = pupae; O = dissected ovaries; F = adult female (FC = without 
ovaries); M = adult male; AeadsxF1, AeadsxF2, and AeadsxM1 = female (F1 and F2) dsx splice 
variant 1 and 2, male (M1) dsx splice variant. All samples in (a-d) are mixed sex except F, FC, O 
and M.   
 
(a) (b) 
(c) 
(e) 
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in origin, and there is no evidence to suggest that Aag2 cells represent a mix of male and 
female cells. Nevertheless, because Salvemini et al. did not specifically test their assay using 
male- and female-only embryonic cells, we cannot unequivocally state that (embryo-derived) 
Aag2 cells are of female origin.  
 
3.4 Transfection Efficiencies of Parental Aag2, Aag2-AF5 and Aag2-AF12 Cells 
 
Characterisation of the single cell clones thus far had highlighted that some may be useful for 
particular avenues of study. Aag2-AF5 cells most closely resemble the parental Aag2 cell line 
(discussed in section 3.1.1), therefore are ideal for use in CRISPR-Cas9 gene editing 
experiments. Aag2-AF10 and Aag2-AF12 clones have a lower or negligible level of PCLV 
RNA than the other single cell clones, indicating a lower level of persistent infection and will 
therefore be useful in studies investigating the effect of persistent infections on arbovirus 
protein expression and viral replication. However as Aag2-AF10 cells exhibit a low rate of cell 
growth the Aag2-AF12 clone is the best suited candidate for PCLV persistence studies. As 
these above-mentioned avenues of study will require transient viral protein expression, 
achieved through plasmid transfection, the transfection efficiency of Aag2-AF5, Aag2-AF12 
and the parental Aag2 cells was assessed.  
 
Parental Aag2, Aag2-AF5 and Aag2-AF12 cell lines were transfected with the EGFP-
expression vector pIEx-1-EGFP (Scott et al., 2010) and after 48 hours, images were captured 
by fluorescence microscopy. Images were compared visually for GFP fluorescence intensity, 
a crude measurement of protein expression levels, and by counting the number of EGFP-
positive cells for each cell line, a measurement of transfection efficiency. The Aag2-AF5 clone 
appeared to have the highest overall level of EGFP expression with the lowest level observed 
in Aag2-AF12 cells (Figure 3.6).  
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The transfection efficiency for each cell line was then estimated by manually counting the 
number of EGFP positive cells and expressing this as a percentage of total cell number per 
field of view. For each cell line at least 900 cells were counted and the average percentage of 
GFP-positive cells determined across three fields of view. Each cell line was analysed in three 
independent experiments and results compared to generate an overall percentage 
transfection efficiency for each cell line. Statistical analyses were conducted using two-tailed 
Student’s t test (Figure 3.7) to determine whether differences in transfection efficiency were 
deemed significant. The average transfection efficiency of parental Aag2, Aag2-AF5 and 
Aag2-AF12 cells was 48%, 56% and 44% respectively. Statistical analysis indicated that no 
significant difference in transfection efficiency was observed between parental Aag2 cells and 
either Aag2-AF5 cells (p=0.167) or Aag2-AF12 cells (p=0.387). As transfection efficiency did 
not significantly differ between cell lines, the low overall GFP expression observed in Aag2-
AF12 cells (Figure 3.6) was likely due to lower protein expression in transfected Aag2-AF12 
cells when compared to transfected Aag2-AF5 or parental cells.  
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Figure 3.6 EGFP-expression in parental Aag2 and Aag2-derived cell clones. Parental Aag2, Aag2-AF5 and AF12 cells were transfected 
with pIEx-1-EGFP and incubated for 48 hours at 28°C. Images were captured using a fluorescence microscope for use in estimating the 
transfection efficiencies of each cell line and are representative of three experiments conducted. These data contributed to Fredericks et al., 
(2019). 
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Figure 3.7. Transfection efficiency of parental Aag2, Aag2-AF5 and Aag2-AF12 cell lines. Cells 
were transfected with pIEx-1-EGFP and incubated at 28°C for 48 hours. Images were captured on 
a fluorescence microscope and transfection efficiency determined by the percentage of EGFP-
expressing cells. Average transfection efficiencies across three experiments taken and error bars 
represent ± standard deviation. A two-tailed Student’s t test with Bonferroni correction was 
conducted. * = p<0.01. These data contributed to Fredericks et al., (2019). 
 
 89 
3.5 Chapter Discussion 
 
In this chapter, the phenotypic analyses in the parental single-cell clones derived from the 
heterogeneous Aag2 cell line was completed. The data produced from these analyses 
(Figures 3.2, 3.3, 3.6 and 3.7) have contributed to a manuscript that is now available on the 
preprint server BioRxiv (Fredericks et al., 2019). 
 
The continued persistent infection of all clones with CFAV was confirmed (section 3.2). 
Surprisingly, for PCLV, some genome segments could not be amplified by RT-PCR for a 
number of clones (section 3.2), even though other viral genome segments were present within 
the same clone.  Bunyavirus replication requires all three genome segments, L, M and S, as 
they encode the RNA-dependent RNA polymerase (RdRp), glycoprotein precursor and 
nucleocapsid protein respectively, all of which are essential for infection and replication in host 
cells (Elliott et al., 1991). The presence of a viral RdRp, which cells do not possess, is essential 
for the replication of negative-sense RNA genome segments. Therefore in the Aag2-AF5 cell 
clone for which only M and S segment amplicons are observed, the L segment must also be 
present below the limit of detection. It is plausible that L segment-containing cell lines could 
lack the M and/or S segment and although the production of infectious virus particles would 
not be possible, the genome segments could be transferred to progeny cells through cell 
division. 
 
Our data therefore suggest that virus must be present in all cell clones, with lower levels of 
certain genome segments present in some clones that are below the limit of detection of the 
RT-PCR assay. To confirm this RT-qPCR could be used to detect the presence or absence of 
the segments, as this technique is more sensitive than endpoint PCR and is capable of 
detecting very low copy numbers of nucleic acid template (Pfaffl and Hageleit, 2001).  
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It is possible that PCLV replication may be suppressed in some cell clones more than others 
due to differences in restriction or host factors, therefore identifying and characterising cellular 
factors that may contribute to this observation could be an interesting future line of 
investigation. 
 
However the data presented in this chapter suggest that the Aag2-AF12 clone is an ideal 
candidate cell line for studying the effects of persistent insect virus infection of mosquito cells 
on arbovirus replication, as the overall levels of detectable persistent virus RNA in this cell line 
were greatly reduced compared to that of other clones and the parental Aag2 cell line. 
 
The presence of persistently infecting viruses in Aag2 cells may have an impact on other virus 
or immune studies using this cell line as positive or negative viral interference may occur when 
infecting with another virus (as mentioned in section 1.1; Salas-Benito and De Nova-Ocampo, 
2015) and the immune system may be primed to a degree due to the persistent infections. To 
overcome this, it would be advantageous to also conduct experiments in an alternative Ae. 
aegypti cell line that is confirmed negative for known persistently infecting viruses. However 
as the presence of PCLV and CFAV has been confirmed in wild Ae. aegypti mosquitoes (Cook 
et al., 2006; Hoshino et al., 2009; Espinoza-Gómez et al., 2011; Yamanaka et al., 2013, Zhang 
et al., 2018), the use of persistently infected cell lines remain relevant for in vitro studies. 
 
The sex of the parental Aag2 cell line and single cell clones were also investigated (section 
3.3). In the publication describing the generation of the original Aag2 cell line (Peleg, 1966), a 
pool of Ae. aegypti eggs were homogenised before being cultured. It is almost certain that this 
would have resulted in a mixed population of male and female cells, since sex determination 
of mosquito eggs is not possible. While the results obtained here are not conclusive, the dsx 
PCR data surprisingly suggests that the cell line could be exclusively female. However, as 
there are no data from Salvemini et al. (2011) to demonstrate which dsx splice variants are 
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present in exclusively female embryos as well as the lack of sex-specific fru variants in 
embryos (Salvemini et al., 2013), the sex of the embryonic Aag2 cells cannot be determined 
using these published dsx and fru primer sets. 
 
Aag2-AF5 cells have been identified as the single cell clone that most closely resembles the 
parental Aag2 cell line in terms of cell morphology and permissiveness to arboviral infection 
(Fredericks et al., 2019). As well providing a homogeneous background for CRISPR-Cas9 
gene editing experiments, this cell clone represents a standardised homogeneous Aag2 cell 
line which will soon be made available to the vector community via ECACC. To verify their 
suitability for molecular studies the transfection efficiency of Aag2-AF5 cells was compared to 
that of parental Aag2 cells. Although both cell lines exhibited similar levels of transfection 
efficiency (Figure 3.7), the GFP signal was brighter in Aag2-AF5 cells (Figure 3.6), suggesting 
higher levels of GFP expression occurred when compared to parental Aag2 cells. This 
confirms data previously generated by Dr Kevin Maringer, in which higher levels of firefly 
luciferase were observed in Aag2-AF5 cells compared to parental cells after plasmid 
transfection (Fredericks et al., 2019). This further verifies the Aag2-AF5 clone as a valuable, 
standardised cell line, as they are readily transfectable, express exogenous proteins to high 
levels and are therefore suitable for molecular work. 
 
Although Aag2-AF12 cells have also been identified as a clone of interest due to the low levels 
of persistent PCLV infection (section 3.2), they may not be as suitable as Aag2-AF5 cells for 
molecular work as protein expression post-transfection appears low compared to parental or 
Aag2-AF5 cells, despite similar transfection efficiencies (Figure 3.7) 
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CHAPTER 4 
Genotypic and Functional Characterisation of 
Putative Knockout Cell Lines 
  
  
 
 
93 
4.1 Chapter Introduction 
 
As vector control remains the most effective method of controlling arbovirus spread, 
understanding viral replication and transmission in the mosquito vector is essential for 
development of effective intervention strategies. Viral replication is a complex process 
involving a plethora of virus-host interactions, with those involving components of host immune 
pathways likely essential for limiting viral replication. Although there is evidence of antiviral 
roles of JAK-STAT and RNAi pathways in mosquitoes (reviewed in Cheng et al., 2016), the 
antiviral roles of Toll and IMD are less well understood and have only begun to be uncovered 
over the last decade (Xi et al., 2008; Luplertlop et al., 2011; Pan et al., 2012).  
 
Previous in vitro and in vivo investigations into the interactions between arboviruses and the 
mosquito immune response have often involved knocking down specific immune pathway 
components, to either activate the pathway by silencing a negative regulator or suppress it by 
silencing a key pathway component (Cirimotich et al., 2009; Souza-Neto et al., 2009; Waldock 
et al., 2012). These experiments were conducted through RNAi-mediated gene silencing, in 
which dsRNAs targeting mature mRNA were introduced into cells or tissues to create gene 
knockdowns (Fire et al., 1998). This technique carries some limitations including silencing 
variability, incomplete gene silencing and ineffectiveness through targeting RNAi-resistant 
tissues or genes expressing proteins with long half-lives (Boutros and Ahringer, 2008). To 
overcome these obstacles CRISPR-Cas9 gene editing techniques can be employed within a 
cell line or organism to achieve gene knockout. 
 
CRISPR-Cas9 technology, derived from the Streptococcus pyogenes bacterial type II 
CRISPR-Cas9 adaptive immune response, was first introduced as a novel tool for gene editing 
in 2013 (Jinek et al., 2013; Cong et al., 2013, Mali et al., 2013) and has since rapidly evolved 
(Adli, 2018). This technique allows precise genome modifications by introducing single guide 
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RNAs (sgRNAs) that hybridise to a specific target sequence, which directs the Cas9 
endonuclease to cleave complementary DNA adjacent to a protospacer adjacent motif (PAM) 
sequence specific to Cas9 (Jiang and Doudna, 2017).  The Cas9 enzyme introduces a blunt-
ended double-stranded break three base pairs upstream of the PAM through the HNH- and 
RuvC-like nuclease domains, which is then repaired by either non-homologous end joining 
(NHEJ), resulting in random base pair insertions and/or deletions, or by homology-directed 
repair (HDR), in which a homologous repair template is inserted at the cleavage site, giving 
rise to a precise modification. 
 
Although genome engineering by CRISPR-Cas9 was first reported for Ae. aegypti mosquitoes 
in 2015 (Kistler et al., 2015), we were the first research group in the field to successfully 
knockout essential immune pathway components in a mosquito cell line using this technology. 
Developed to study the effect of an inactive RNAi response, our Aag2-AF5-derived dicer-/- cell 
line Aag2-AF319 has been phenotypically and genotypically confirmed as a successful 
knockout, has recently been utilised and published in RNAi studies (Varjak et al., 2017a, 
Varjak et al., 2017b) and will soon be available through ECACC. Aag2 knockout cell lines 
lacking essential signalling components in the other innate immune pathways would also be 
invaluable tools for the arbovirus and vector research communities. 
 
4.1.1 Previous work 
Previous CRISPR-Cas9 experiments using the phenotypically characterised Aag2-AF5 cell 
line involved the introduction of mutations within essential immune pathway genes resulting in 
their loss of function and prevention of downstream pathway-specific induction (workflow 
shown in Figure 3.1). Of interest to this project, putative single and double knockout cell lines 
lacking the NF-κB genes Rel1A (Toll pathway regulator) and/or Rel2 (IMD pathway regulator) 
were created and functionally characterised by either the use of luciferase reporters or 
measuring gene induction of pathway-specific genes by RT-qPCR (Figure 4.1). The single 
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and double knockout cell lines will be used in future experiments to test the effects of loss of 
immune function on the replication of DENV.  
 
In this chapter, PCR-amplified sequences of the aforementioned putative Rel1A and Rel2 
knockout cell lines were analysed by Sanger sequencing to genotypically characterise the 
indel from CRISPR-Cas9 gene editing. Due to the lack of indel identification in the putative 
Rel2-/- cell lines, their knockout status was re-determined by RT-qPCR analysis of IMD 
activation.  
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Figure 4.1. Loss of IMD functionality in CRISPR-Cas9 Rel2 knockout cell lines.  Previous 
experiment demonstrating loss of IMD pathway function in Aag2-AF66 and Aag2-AF69 clones 
relative to parental Aag2. Cells were stimulated with 1000 CFU/cell and Defensin D expression was 
measured by RT-qPCR 24 hours post-stimulation (data generated by Dr Kevin Maringer). 
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4.2 Indel characterisation in putative IMD and/or Toll pathway loss-of-function 
mutants 
 
Previous attempts to define indels in IMD and/or Toll pathway functional knockout Aag2 cells 
generated in our laboratory were only partially successful. For some mutants, previous 
sequencing attempts returned only WT sequence, suggesting any potential indels may lie 
outside of the sequenced region. For others, PCR amplification was unsuccessful, possibly 
because primer-binding sites were lost due to the indel. Therefore, in the experiments 
described here (workflow shown in Figure 4.2a), PCR primers were designed to bind further 
up- and downstream from the sgRNA-binding site to amplify larger amplicons (~1.5-2.5 kb) 
(example schematic diagram of primer and sgRNA binding sites within Rel2 gene shown in 
Figure 4.3). 
 
For putative mutant cell lines generated using CRISPR-Cas9 sgAF12 targeting Rel1A exon 2 
(Table 2.1), it was not possible to design specific primers that amplified the desired product 
(Figure 4.2b), likely due to the highly repetitive nature of the genomic sequence. Altered 
annealing temperature and Mg2+ concentration were also tested in the attempt to increase 
PCR specificity, but were unsuccessful in amplifying the desired product (data not shown). 
Indels for these cell lines could therefore not be determined.  
 
Target sequence amplification was successful for Rel1A of the putative Rel1A-/-Rel2-/- mutants 
generated using CRISPR-Cas9 sgAF14 targeting Rel1A exon 3 (Figure 4.2c). Sanger 
sequencing revealed a 28-nucleotide deletion within exon 3 of one allele (Figure 4.4a), while 
the second allele was WT across the region sequenced (Figure 4.4b). While target sequences 
were successfully amplified for all putative Rel2-/- mutants (Figure 4.2d), sequencing results 
revealed all amplified regions to be WT (data not shown).  A summary of successful indel 
sequencing can be found in Table 4.1. 
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Gene Rel1A Rel2 
sgRNA sgAF12 sgAF14 sgAF18 + sgAF19 
                       
Test and optimise 
primers against parental 
Aag2 gDNA for PCR 
û 
(b) 
ü 
 
ü 
 
PCR using relevant Aag2 
knockout cell lines (see 
Table 2.1) 
- ü 
(c) 
ü 
(d) 
Clone PCR products into 
pJET vector, transform 
and mini prep picked 
colonies 
- ü 
 
ü 
 
Sequence and analyses - ü 
 
ü 
 
 
 
 
 
 
 
 
Figure 4.2. Indel characterisation in putative knockout cell lines. (a) Workflow for characterising 
indels in Aag2 knockout cell lines. Ticks represent successfully completed steps, crosses represent 
unsuccessfully completed steps. (b) PCR amplification of WT Rel1A genomic sequence using primer 
sets prLEW1-4 (Table 2.3). Arrowheads represent the expected size of the PCR products. (c) PCR 
Download gene FASTA sequence from VectorBase (Ae. aegypti L3 reference) 
Map out introns, exons, sgRNA sites and previous sequencing primers 
Submit gene sequence, including ~1.5 kb flanking region either side of sgRNA target 
site, to Primer-BLAST 
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amplification of Rel1A sequence surrounding the sgAF14 sgRNA target site in parental Aag2 cells, the 
WT Aag2-AF5 clone used for CRISPR-Cas9-generated knockouts, and resulting Aag2-AF256 mutant 
clone using primer pair prLEW9. (d) PCR amplification of Rel2 sequence surrounding the 
sgAF18/sgAF19 sgRNA target site in parental Aag2 cells, Aag2-AF5 cells, and knockout cells (Aag2-
AF66, Aag2-AF69 and Aag2-AF92) using primer pair prLEW6. 
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Figure 4.3  PCR primer locations within the Rel2 gene. Red and navy sequences represent exons 
and introns respectively within the Rel2 gene (AAEL007624), as defined in the L3 Ae. aegypti 
reference genome. sgRNA binding sites, previously used indel sequencing primers and the newly 
designed primers, prLEW6 are highlighted in the sequence. 
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(a) Rel1A Deletion in Aag2-AF251 cells (Allele 1, exon 3) 
 
                 125       184 
 GATCCCCGGCGTCCACAGCACCCCGGAGCAGAAAACCTTCCCCGGGATCGAAATCCGGGG 
 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
 GATCCCCGGCGTCCACAGCACCCCGGAGCAGAAAACCTTCCCCGGGATCGAAATCCGGGG 
 
       185       244 
 CTACAAGGGCCGAGCGGTGGTGGTGGTGTCCTGCGTTACCAAGG----GC---------- 
 ||||||||||||||||||||||||||||||||||||||||||||    ||           
 CTACAAGGGCCGAGCGGTGGTGGTGGTGTCCTGCGTAACCAAGGACCCGCCCTACCGGCC 
 
       245       304 
 ------------TCTGGTCGGCAAGGAGGGCTGCAAGAAGGGAGTCTGCACGGTCGAGAT 
             |||||||||||||||||||||||| ||||||||||||||||||||||| 
 CCATCCGCACAATCTGGTCGGCAAGGAGGGCTGCAAAAAGGGAGTCTGCACGGTCGAGAT 
 
 
 
 
(b) Rel1A WT Sequence in Aag2-AF251 cells (Allele 2, exon 3) 
 
 
                 125       184             
 GATCCCCGGCGTCCACAGCACCCCGGAGCAGAAAACCTTCCCCGGGATCGAAATCCGGGG 
 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
 GATCCCCGGCGTCCACAGCACCCCGGAGCAGAAAACCTTCCCCGGGATCGAAATCCGGGG 
 
       185       244 
 CTACAAGGGCCGAGCGGTGGTGGTGGTGTCCTGCGTTACCAAGGATCCGCCCTACCGGCC 
 |||||||||||||||||||||||||||||||||||| |||||||| |||||||||||||| 
 CTACAAGGGCCGAGCGGTGGTGGTGGTGTCCTGCGTAACCAAGGACCCGCCCTACCGGCC 
 
       245       304 
 CCATCCGCACAATCTGGTCGGCAAGGAGGGCTGCAAGAAGGGAGTCTGCACGGTCGAGAT 
 |||||||||||||||||||||||||||||||||||| ||||||||||||||||||||||| 
 CCATCCGCACAATCTGGTCGGCAAGGAGGGCTGCAAAAAGGGAGTCTGCACGGTCGAGAT 
 
 
 
 
Figure 4.4. Alignment of Sanger sequencing data for the Aag2-AF256 mutant clone against 
genomic Rel1A sequence (L3 reference genome). (a) Allele 1 has a 28-nucleotide deletion in the 
sgAF14 sgRNA binding site (bold, underlined). (b) Allele 2 is WT sequence in the region sequenced. 
The top sequence is that of the Aag2-AF251 knockout cell line and the bottom sequence is of Rel1A 
from the Ae. aegypti L3 reference genome.
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Table 4.1. Summary of sequenced Aag2 knockout cell lines. Numbers in subscript denote nucleotide position within exon; size of deletion is given in square 
brackets; round brackets specify exon location of indel. Impact of nucleotide mutation on protein sequence is specified; total length, and length of WT sequence 
(square brackets) is specified.  
 
   Allele 1 Allele 2 
Target Gene Cell Clone Gene Mutation Impact on 
Protein 
Mutation Impact on 
Protein 
 
Rel2 
 
Aag2-AF66 
 
Rel2 
 
None in region sequenced 
 
WT 
 
None in region sequenced 
 
WT 
 Aag2-AF69 Rel2 None in region sequenced WT None in region sequenced WT 
 Aag2-AF92 Rel2 None in region sequenced WT None in region sequenced WT 
       
Rel1A + Rel2 Aag2-
AF256 
Rel1A 224CAAGG-- [∆28]—TCTGG261 (exon 3) STOP; 210 [108 
WT] 
None in region sequenced WT 
  Rel2 1 169GACAC--[∆4]--AAATA182 (exon 2) STOP; 88 [58 
WT] 
168CGACA--[∆14]—GCGAG191 (exon 2) STOP; 66 [57 
WT] 
 
 
1 Mutations in this gene were previously determined. 
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4.3 IMD Functionality Assay in Putative Rel2-/- Cell Lines 
 
Although indel sequencing data suggested that the putative Rel2-/- cell lines were homozygous 
WT, these clones had previously been shown to lack IMD pathway functionality (Figure 4.1). 
Therefore, IMD pathway function was re-tested for current cell line stocks of the putative Rel2-
/- clones Aag2-AF66 and Aag2-AF92; the Aag2-AF69 clone was not tested due to mycoplasma 
contamination of the stocks. Parental Aag2 cells and the Aag2-AF5 clone were included as 
representatives of WT cells with a functional IMD response. Each cell line was stimulated with 
heat-inactivated E. coli 24 hours post-seeding and IMD-regulated gene expression measured 
by RT-qPCR after a further 24 hours. As expected, Defensin D was induced in stimulated cells 
compared to unstimulated cells by a factor of over one hundred in both parental Aag2 and 
Aag2-AF5 cells (Figure 4.5). There was no significant difference in induction between Aag2-
AF66 and Aag2-AF5 cells (p=0.049). However the induction of Defensin D in Aag2-AF92 was 
significantly higher than in Aag2-AF5 (p=9.058E-6) (Figure 4.5). Combined with the 
sequencing data (section 4.3), this suggests that Rel2 is not knocked out in these cell lines. 
 
Overall, while it was not possible to sequence all putative Rel1A-/- mutants, the data suggest 
that none of the cell line stocks, including what were previously considered functional Rel2-/- 
mutants, could be identified as homozygous knockout mutants.  
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Figure 4.5. RT-qPCR assay for Rel2-regulated Defensin D induction by heat-inactivated E. 
coli.  RT-qPCR analysis of Defensin D induction in parental Aag2 cells, WT Aag2-AF5, and mutant 
Aag2-AF66 and Aag2-AF92 clones. Data show mean relative induction of Defensin D in biological 
triplicates, error bars represent standard error of the mean. A two-tailed Student’s t test with 
Bonferroni correction was conducted, significance noted as p≤0.0167. ns = not significant, ** = 
p<0.01. 
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4.4 Chapter Discussion 
 
Following the successful generation of the validated dicer-/- Aag2 cell line Aag2-AF319, our 
laboratory previously developed putative immune gene knockout cell lines lacking Rel2 and/or 
Rel1A to provide useful tools to study IMD and Toll pathway effects on arboviral replication, 
with Rel2-/- Aag2 cell line being a key tool for future IMD pathway experiments following on 
from this project. 
 
Designing primers to characterise our putative Rel2-/- and Rel1A-/- knockout cell lines proved 
challenging. At the time of design, the available reference genome for Ae. aegypti was the L3 
release, which was an improved version of the first draft sequence presented a decade 
beforehand (Nene et al., 2007). The sequence was poorly assembled and annotated due to 
the high repetitive sequence content (>50%) and fragmented nature of the genome (Nene et 
al., 2007). Combined with the challenge of designing primers in genome regions containing 
highly repetitive sequences, only two out of twelve primer sets tested amplified the desired 
product. Significant advances in sequencing of the Ae. aegypti genome have recently been 
made and in December 2017 the L5 reference genome was released (Matthews et al., 2018). 
93% fewer contigs were produced from this sequencing, allowing better assembly and a 
greatly improved gene set annotation. This will greatly aid design of future primer sets for 
specific amplification within the Ae. aegypti genome. 
 
Based on sequencing data (section 4.2) and RT-qPCR analysis of immune gene induction 
(section 4.3), it was concluded that all current putative Rel2-/- cell line stocks are WT for Rel2. 
Nevertheless, initial functional screens performed by Dr Kevin Maringer indicated that IMD 
function was disrupted in these clones (Figure 4.1). CRISPR-Cas9 gene editing is not 100% 
effective, with reported NHEJ efficiencies of 20-60% in murine genomes (Yang et al., 2013; 
Wang et al., 2013) and it is possible that the clonal selection process may not have been 
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sufficient to generate a WT-free cell line. Alternatively, the cell lines may have been 
contaminated whilst being handled in tissue culture after the initial functional characterisation 
had been conducted. Either way, future work will include new knockout cell lines being 
generated using an alternative and improved CRISPR-Cas9 gene editing approach to 
overcome some of the technical hurdles experienced in this project (see section 7.3, 
Discussion).  
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CHAPTER 5 
DENV-2 IMD Pathway Antagonist Screen 
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5.1 Chapter Introduction 
 
Viruses, as obligate intracellular parasites, are in a constant battle with host immune defences, 
and this fight has long been recognised as a key factor driving evolution of both virus and host, 
as one evolves so must the other. Viruses must overcome host immunity to allow replication 
and subsequent transmission. Arboviruses face this hurdle not only in their host but also in 
their haematophagous insect vector(s), two very distinct host groups that present different 
immune challenges to the virus. To achieve this, arboviruses suppress host immune 
responses through expression of immune antagonists, thereby allowing a productive infection 
to be established. As discussed in the introduction (section 1.5.4.1), antagonistic roles of 
DENV proteins NS2A, NS2B/3, NS4A, NS4B and NS5 targeting IFN production and signalling 
have been elucidated in vertebrate systems. However, no DENV proteins have yet been 
identified as immune antagonists in their mosquito hosts, although there is evidence that viral 
genomic 3’ UTR degradation products, known as subgenomic flaviviral RNAs (sfRNAs), can 
inhibit the Toll pathway in the salivary glands of DENV-2-infected mosquitoes (Pompon et al., 
2017).  
 
Although not a lot is known about the antiviral roles of IMD signalling, a number of studies 
have shown that various arboviruses antagonise the pathway upon infection. In Aedes cells 
lines, Semliki Forest virus (SFV) and CHIKV downregulate IMD, Toll and JAK-STAT signalling 
and DENV can inhibit the induction of AMPs regulated by Toll and IMD pathways (Fragkoudis 
et al., 2008; Sim et al., 2010; McFarlane et al., 2014). Targeted pathway inhibition highlighted 
by these findings are suggestive of an antiviral function of the IMD pathway. Only one viral 
antagonist of the IMD pathway has been identified to date; a family of proteins encoded by 
insect DNA viruses that are homologous to the Drosophila spp. immunomodulatory cytokine 
Diedel (Lamiable et al., 2016).  
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Data from both in vitro and in vivo studies suggest that DENV infection does not induce IMD 
signalling in Ae. aegypti (Xi et al., 2008; Souza-Neto et al., 2009). However this may be due 
to viral suppression of the pathway, a hypothesis supported by the finding that several AMPs 
are downregulated during early infection stages, possibly before the vector can mount an 
immune response (Ramirez and Dimopoulos, 2010).  
 
5.1.1 Previous work 
Our group previously demonstrated that IMD signalling can be induced by viral PAMPs, such 
as infection with CrPV and in the presence of the polyinosinic:polycytidylic acid (poly [I:C]; 
Figure 5.1a,b), which is structurally similar to viral dsRNA. However, our data have also shown 
that DENV-2 infection does not induce IMD signalling in the Aag2 cell line (Figure 5.1c,d), 
recapitulating in vivo data from other research groups (Xi et al., 2008). Additionally, it was 
shown that DENV-2 infection reduces subsequent IMD activation by classical IMD immune 
stimuli such as heat-inactivated bacteria (Figure 5.2a-c). Therefore it was hypothesised that 
DENV-2 is able to antagonise IMD immune signalling. To study this, our group developed an 
RT-qPCR assay to assess IMD pathway induction by measuring expression levels of validated 
IMD-regulated genes in Aag2 cells (Figure 5.3). 
 
In this chapter, DENV-2 protein expression plasmids (Shah et al., 2018) were tested and 
optimised for expression in Aag2 cells and detection by immunoblot analysis for use in the 
IMD signalling RT-qPCR assay. DENV-2 IMD pathway antagonist screen experiments were 
conducted, analysing the effects elicited by transiently expressed DENV-2 proteins on IMD 
signalling to identify potential inhibitory functions. 
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Figure 5.1. IMD signalling is induced by viral PAMPs but not by DENV-2 in Aag2 cells. IMD 
signalling was measured by RT-qPCR of the IMD-regulated gene, Cecropin B. (a) IMD signalling is 
induced by poly(I:C) transfection. (b) CrPV infection at MOI 2 induces IMD signalling. (c) Induction 
of IMD signalling after E. coli stimulation or DENV-2 infection at MOI 2 over time. (d) DENV-2 growth 
curve measuring levels of intracellular viral RNA at MOIs 0.02 and 2. Data generated by Dr Kevin 
Maringer. 
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Figure 5.2. DENV-2 antagonises the IMD pathway. (a) RT-qPCR experimental outline. (b) 
Induction of IMD signalling by E. coli is reduced during DENV-2 infection. IMD signalling assessed 
by RT-qPCR of the IMD-regulated genes (b) Defensin D and (c) Cecropin B. Data generated by Dr 
Kevin Maringer. 
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5.2 Optimisation of Immunoblot Conditions 
 
5.2.1. Optimisation of lysis methods and primary antibodies 
Before immunoblot detection of the DENV-2 proteins can be assessed, primary antibodies 
first had to be optimised. As the DENV-2 proteins are all Strep-tagged, an anti-Strep-II primary 
antibody was tested as well as an anti-tubulin antibody for the detection of the loading control. 
During initial experiments, immunoblots showed significant protein trails for all lysates (data 
not shown), possibly due to high gDNA content in the samples. To reduce this problem, 
sample harvest and lysis conditions were optimised. 2x SDS-PAGE loading dye, RIPA buffer 
and 2x disruption buffer (DB) were tested with and without the addition of benzonase nuclease 
(see Table 2.4 for lysis buffer details). Samples were either sonicated or syringed post-lysis. 
 
Figure 5.3 Experimental set up for DENV-2 protein IMD antagonist screen. Transfections were 
performed in parallel in 96- and 12-well formats. Aag2 cells were seeded and transfected before 
being stimulated 48 hours post-transfection with an immune stimulant, such as heat-inactivated E. 
coli. Cells were harvested 72 hours post-transfection. Lysates from 96-well plates were used for 
RT-qPCR detection of IMD-regulated genes (Defensin D, Cecropin D, Cecropin B) and RpS7 as a 
control. Lysates from 12-well plates were used for detection of DENV-2 proteins by immunoblot. 
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The Strep-tagged enhanced green fluorescent protein (EGFP) protein bands were not as well 
resolved when samples were lysed in SDS-PAGE buffer compared to other lysis conditions 
(Figure 5.4a). In the samples lysed directly in SDS-PAGE buffer (Figure 5.4a, top panel, first 
four lanes), the protein band obtained from the sample disrupted by syringing was not as well 
resolved as sonicated samples, though sonication for 90 seconds did not provide better lysis 
than sonication for 30 seconds. The addition of benzonase did not reduce the observed protein 
tails for any of the buffers (Figure 5.4a). Since samples lysed in RIPA buffer showed two bands 
for Strep-EGFP, DB buffer was used moving forward.  
 
While comparing the harvest and cell lysis methods, immunoblots were also probed for tubulin 
(Figure 5.4a). Two tubulin bands were observed for RIPA lysates, compared to only one band 
for samples lysed in DB. Tubulin bands were not detected for samples lysed in SDS-PAGE 
loading dye. Overall, the decision was made to use DB for all future experiments.  
 
Primary antibody dilutions were then re-optimised for immunoblotting.  The anti-Strep-II 
antibody, was tested at 1:1000, 1:2000 and 1:8000 dilutions using Strep-EGFP. While all 
dilutions gave detectable bands (Figure 5.4b), the 1:2000 dilution was chosen for future 
experiments as it was the highest dilution giving clear bands. The 1:2000 dilution was chosen 
for the anti-tubulin antibody for the same reason (Figure 5.4c).   
 
5.2.2 Testing DENV-2 protein expression 
Prior to performing the RT-qPCR screen plasmids were tested to ensure that all DENV-2 
proteins were expressed (plasmids listed Table 2.2). The DENV-2 protein expression plasmids 
and an EGFP-expressing control plasmid were transfected into Aag2 cells and samples were 
 
 
  
 
 
113 
 
 
              
 
 
 
 
 
 
 
                       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4 Optimisation of cell lysis and primary antibody conditions for immunoblotting. 
Aag2 cells were transfected with a Strep-tagged enhanced green fluorescent protein (EGFP) 
expressing plasmid. (a) Samples were harvested in either 100 µl 2x SDS-PAGE, RIPA, or 2x DB 
buffer, with and without benzonase. Samples were either sonicated 3 x 10 sec, 9 x 10 sec or 
syringed using a 23G needle. Proteins were separated by SDS-PAGE and subjected to 
immunoblotting using a 1:2000 dilution of either anti-Strep-II or anti-tubulin primary antibodies. (b,c) 
Samples were harvested in 100 µl 2x DB buffer. SDS-PAGE and immunoblotting were conducted 
using (b) 1:1000, 1:2000 and 1:8000 dilutions of anti-Strep-II primary antibody, or (c) 1:1000, 
1:2000, and 1:5000 of anti-tubulin primary antibody. 
 
 
 
 
(b) 
       1:1000           1:2000           1:5000 
(c) 
(a) 
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harvested for SDS PAGE and immunoblot analysis 48 hours post-transfection. A plasmid 
expressing NS2B and NS3 together (NS2B/3) was also included as these constitute the viral 
protease which has been shown to antagonise vertebrate type I IFN production (Aguirre et al., 
2012). Only the EGFP positive control, capsid with and without the transmembrane domain 
(C and CA), NS2B/3 and NS1 proteins were detected (Figure 5.5). As most of the DENV-2 
proteins were not observed, further optimisation was carried out to improve both protein 
expression and detection.  
 
 
 
 
 
Figure 5.5. DENV-2 protein expression in transfected Aag2 cells. Aag2 cells were transfected 
with DENV-2 protein expression plasmids or an EGFP-expressing positive control plasmid and 
harvested 72 hours post-transfection for immunoblotting. White arrows highlight detected bands 
that are of the correct size for the relevant protein. 
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5.2.3 Comparison of denaturing conditions, non-optimised and mosquito codon 
optimised (MCO) DENV-2 plasmids 
As the majority of the DENV proteins could not be detected and due to long-term storage and 
transport, DENV-2 protein expression plasmids were checked on an agarose gel (Figure 5.6). 
The DENV-2 protein expression plasmids come in both MCO and non-optimised forms and 
all were tested here (plasmid list Table 2.2). For all stocks the vast majority of plasmids were 
supercoiled, therefore it was assumed the plasmid preparations had not degraded and were 
in good condition for use. 
 
 
 
 
 
Figure 5.6. Analysis of plasmid stock integrity. All plasmid stocks used in this project were 
analysed by electrophoresis on a 1% agarose gel. Plasmids listed in Table 2.2. 
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A number of DENV-2 proteins are difficult to express in eukaryotic cells, therefore protein 
isolation conditions were previously optimised by Ericka Kirkpatrick (Icahn School of Medicine 
at Mount Sinai). Lysates were either boiled at 95°C, heated at 45°C, or not heated at all before 
SDS-PAGE (as specified in Table 5.1). To simplify the experimental set up, these conditions 
were re-tested and compared with simply boiling all samples at 95°C. In both experimental 
conditions, the structural proteins prM and E, as well as NS2A and NS4A, were not observed 
(Figure 5.7a). The different heat treatments did not make a great difference in the overall 
detection of the DENV-2 proteins, apart from for NS5, which was only detected at low levels 
when samples were not boiled. Therefore, it was decided that all samples would be boiled at 
95°C before SDS-PAGE to simplify the setup of future experiments. 
 
 
No Boiling Heat at 42°C for 10 minutes Boil at 95°C for 20 minutes 
pAc-MCO-CA pAc-MCO-NS4B pAc-MCO-C 
pAc-MCO-NS2A  pAc-NS1 
pAc-MCO-NS2B  pAc-EGFP 
pAc-MCO-NS2B/3   
pAc-MCO-NS3   
pAc-MCO-NS4A   
pAc-MCO-NS5   
 
 
Due to poor expression in mosquito cell culture, MCO versions of the (non-optimised) DENV-
2 plasmids with the exception of NS1 were previously generated (Shah et al., 2018), where 
the DENV-2 genes are codon optimised for expression in mosquito cells, which should 
improve the efficiency of translation and therefore the expression of the genes. To test this, 
transfections with MCO versions of the DENV-2 protein expression plasmids were compared 
with the non-optimised DENV-2 plasmids (Figure 5.7a,b). Overall, DENV-2 proteins were 
Table 5.1 Previously optimised denaturing conditions for individual DENV-2 protein lysates. 
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better detected in samples transfected with MCO plasmids than with non-optimised versions. 
Notably, NS4A expression was only detected from the MCO plasmid.  Therefore for future 
experiments, MCO plasmids will be used in transfections and all lysates will be boiled at 95°C 
before SDS-PAGE.  
 
 
 
 
 
Figure 5.7. Testing non-optimised plasmids, mosquito codon optimised (MCO) plasmids and 
different post-lysis conditions. Aag2 cells were transfected with 3 µg of (a) non-optimised DENV-
2 plasmids or (b) MCO DENV-2 plasmids and harvested 72 hours post-transfection. Prior to SDS-
PAGE and immunoblotting, lysates were either all boiled at 95°C for 5 minutes or were subjected to 
one of three conditions as previously optimised (Table 5.1). White arrowheads highlight detected 
bands that are of the correct size for the relevant protein. 
 
(a) 
(b) 
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With these optimised conditions, the majority of proteins were detectable. However the 
structural proteins E and prM have not been observed in any of the experimental conditions. 
NS5 was also not detected using the MCO plasmid although previous detection using the non-
optimised version was very weak. 
 
5.2.4. Effects of inhibiting proteasomal degradation on DENV-2 protein expression 
Detection of many DENV-2 proteins was weak, which could be due to cells targeting these 
proteins for degradation. To test this, the proteasome inhibitor MG132 was added to cells 
transfected with MCO plasmids encoding C, NS3, NS2B/3, NS4A, NS4B and NS5 18 hours 
before harvesting. These conditions had previously been optimised by Dr Priya Shah 
(University of California, Davis, CA USA), who generated these plasmids while working in the 
laboratory of Prof. Raul Andino (University of California at San Francisco). The addition of 
MG132 to these samples, with the exception of NS5, produced stronger protein bands than in 
 
Figure 5.8. Effect of proteasome inhibition on DENV-2 protein detection by immunoblot. Aag2 
cells were transfected with 3 µg of various plasmids. At 18 hours before harvest, cells were treated 
with 20 µM MG132 or left untreated. Samples were harvested in 2x DB 72 hours post-transfection. 
White arrowheads highlight the location of faint protein bands. 
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the absence of the inhibitor, suggesting these DENV-2 proteins are being degraded to a 
degree in the absence of MG132 (Figure 5.8).  
 
5.2.5 Comparison of immunoblot detection methods to enhance protein visualisation 
All DENV-2 protein-expression plasmids were then tested with the addition of MG132 18 hours 
before harvesting. An additional plasmid was included which expressed NS5 N-terminally 
linked with EGFP followed by ubiquitin. This construct was previously generated to have NS5 
in its polyprotein cleavage context whereby ubiquitin cleavage by cellular ubiquitin hydrolases 
allows NS5 to have full functionality (Ashour et al., 2009). However, this construct did not 
result in NS5 expression and was therefore not used in the following screen experiments. 
Expression of all other DENV-2 proteins was detected (Figure 5.9), however NS2A, NS4B and 
NS5 proteins were only weakly observed. As protein expression was visualised using a near 
infra-red (NIR) detection system, the weakly expressing proteins as well as NS4A and NS3 
without MG132 were analysed using an ECL detection system in the attempt to improve 
detection. As ECL detection involves a dynamic enzymatic reaction, visualisation of these 
previously weakly detected proteins was enhanced using this detection method after a one-
minute exposure (Figure 5.9), with the weakest protein NS4B being more apparent after a 
two-minute exposure. Strep-tagged DENV-2 proteins in subsequent experiments were 
visualised by ECL and tubulin by NIR. This also allowed the elimination of MG132 from 
subsequent experiments so that immunoblotting samples mimicked the samples processed 
for RT-qPCR analysis. 
 
5.3 DENV IMD Pathway Antagonist Screen 
Once the conditions had been optimised for immunoblotting, the DENV IMD pathway 
antagonist screen experiments could be conducted. The RT-qPCR platform had previously  
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Figure 5.9 Immunoblot detection method comparison. Aag2 cells were transfected with 3 µg of 
DENV-2 expression plasmids and harvested 72 hours post-transfection. After SDS PAGE and 
antibody incubation, protein bands were detected by (a) NIR or (b) ECL, to improve detection of 
fainter protein bands. White arrowheads highlight detected bands that are of the correct size for the 
relevant protein. 
 
(a) 
 
 
(b) 
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been developed and optimised by Dr Kevin Maringer and is summarised here: To measure 
the levels of IMD induction, IMD effector genes were shortlisted from a literature search based 
on pathway-specific induction in vivo (Xi et al., 2008; Souza-Neto et al., 2009; Zou et al., 2011), 
screened for Rel2 binding sites in their promoters and validated for IMD-specificity in the Aag2 
cell line by gene knockdown assays (data not shown). The primers that were designed for 
these selected validated IMD-regulated AMP genes - Defensin D, Cecropin B and Cecropin 
D - as well as housekeeping gene RpS7 were optimised for qPCR to give amplification 
efficiencies within the range of 90-110% and all AMP gene primers within 4% of the efficiency 
of RpS7.  
 
Melt curve analyses were conducted for each experiment to assess the specificity of the 
primers in each reaction.  A single peak demonstrated a unique product being amplified in a 
given reaction, which was observed for Defensin D, Cecropin D and RpS7 reactions. However, 
qPCR reactions amplifying Cecropin B generated multiple peaks in the melt curve analysis 
(example Figure 5.10a), indicating a lack of primer specificity, sub-optimal reagent 
concentrations and/or reaction conditions, resulting in non-specific product amplification. This 
was confirmed by subsequently running a selection of multi-peak samples on an agarose gel, 
in which seven amplicons of varying sizes were detected (Figure 5.10b). Consequently, 
Cecropin B was not included as a measure for IMD signalling induction in the screen 
experiments.  
 
To determine if one or more of the DENV-2 proteins can antagonise IMD signalling, each of 
the DENV-2 proteins were expressed from pAc-backbone plasmids and tested individually 
using our IMD-specific RT-qPCR platform to measure levels of IMD signalling in Aag2 cells 
stimulated with the classical IMD stimulant, Gram negative bacteria (Figure 5.3).  
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Figure 5.10 Analysis of Cecropin B qPCR primer specificity. (a) Example of qPCR melt curve 
analysis using Cecropin B primers. Melt curve analysis shows the specificity of primers by 
incrementally increasing the annealing temperature. The multiple peaks observed indicate a lack of 
primer specificity. (b) Confirmation of lack of primer specificity in melt curve multi-peak unstimulated 
Aag2 samples by agarose gel electrophoresis. Black arrowheads highlight the multiple products 
observed. 
(a) 
(b) 
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For immunoblot and RT-qPCR analysis, Aag2 cells were transfected with 3,000 ng or 300 ng 
respectively of each DENV-2 protein expression plasmid as well as controls, pAc-2xStrep(C) 
(referred to as empty vector) and pAc-EGFP. 48 hours post-transfection IMD signalling was 
induced by the addition of 1000 CFU/ml HI E. coli and samples harvested after a further 24 
hours. The expression of all DENV-2 proteins and EGFP control was confirmed by ECL 
detection of immunoblot samples.  
 
Three successful screens were completed and immunoblots were conducted to ensure that 
the proteins were successfully expressed such that results obtained from the RT-qPCR were 
due to the presence of the relevant DENV-2 proteins. A representative example of immunoblot 
data from one of the experimental repeats shows that all DENV-2 proteins were expressed, 
although MCO NS2A was only detected when overexposed due to low level protein 
expression, confirmed by the tubulin loading control (Figure 5.11). 
 
Prior to the RT-qPCR screen analysis, the level of IMD induction was assessed by comparing 
relative induction levels of stimulated and unstimulated samples transfected with the empty 
vector control. This would confirm that the pathway was activated to sufficient levels to allow 
the study of signalling inhibition. Induction levels of Defensin D and Cecropin D ranged from 
14-62 fold (Figure 5.12a) and 14-31 fold (Figure 5.12b) respectively providing sufficient 
pathway induction to study potential antagonistic properties of the expressed DENV-2 
proteins.  
 
To analyse the effects of DENV-2 proteins on IMD signalling, relative induction values of 
Defensin D and Cecropin D in the presence of each DENV-2 protein were normalised to those 
in the presence of the EGFP control, an inert protein that should elicit no antagonistic function 
(Jensen, 2012). RT-qPCR data generated from the three screens amplifying Defensin D show  
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Figure 5.11 Representative immunoblot of DENV-2 IMD antagonist screen samples. Aag2 
cells were transfected with 3 µg of DENV-2 plasmids, harvested 72 hours post-transfection and 
subjected to SDS PAGE and immunoblotting. Strep-tagged DENV-2 proteins were detected by ECL 
and tubulin loading control by NIR. White arrowheads highlight detected proteins of the expected 
size. 
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Figure 5.12 IMD-specific gene induction in the presence of DENV-2 proteins. RT-qPCR 
analyses of validated IMD-specific gene expression in HI E. coli stimulated and unstimulated Aag2 
cells. Defensin D (a,c) and Cecropin D (b,d) levels were analysed and IMD pathway fold induction 
calculated (a,b) or relative percentage induction values normalised to the relative induction of IMD 
in the presence of EGFP (c,d). Data points represent average relative induction within an individual 
experiment, blue and green columns represent the average relative induction between experiments 
and error bars represent standard deviation. Paired two-tailed student’s t tests were conducted: 
*p<0.05, **p=0.008 (expressed DENV-2 proteins compared to stimulated EGFP sample); #p<0.05 
(stimulated compared to unstimulated empty vector control sample). 
(a) 
 
 
(b) 
 
 
(c) 
 
 
(d) 
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that the majority of DENV-2 proteins – C, NS1, NS2A, NS2B, NS3, NS2B/3 and NS4B – had 
no significant effect on the activation of the IMD pathway although the values between 
experiments varied substantially (Figure 5.12c), potentially due to a number of factors that will 
be explored later in this chapter (Section 5.3). However, a significant reduction of IMD pathway 
stimulation was observed for NS4A across all three experiments with an average induction of 
64% compared to that of EGFP (p=0.02). Data also suggests NS5 had a significant stimulatory 
effect on IMD pathway induction with an average induction of 125% (p=0.008). Cecropin D 
induction also varied considerably between experiments (Figure 5.12d). Although there was 
a decrease in pathway induction in the presence of NS4A across all three experiments, it was 
not a significant reduction (p=0.152). Only the presence of DENV-2 NS4B caused a significant 
difference in Cecropin D levels, with an average IMD induction of 149% (p=0.03).  
 
The results of IMD induction measuring Defensin D and Cecropin D together suggest that 
DENV-2 NS4A is a tentative IMD signalling antagonist, although further optimisation and 
experimental repeats may be needed to decrease variability between experiments and 
increase statistical power. 
 
5.3 Chapter Discussion 
 
The screen for DENV-2 IMD pathway antagonists involves three experimental stages; immune 
stimulation of Aag2 cells transiently transfected with DENV-2 protein expression plasmids, 
confirmation of DENV-2 protein expression by immunoblot, and detection of immune gene 
induction by RT-qPCR. The optimised conditions for immunoblotting are summarised in Table 
5.2. 
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 Optimised Conditions 
Transfection 3 µg plasmid DNA encoding DENV-2 MCO genes (exception of 
NS1), EGFP and 2xStrep (empty control) with 2 µl TransIT-Insect 
reagent in 100 µl serum-free L-15 media. 1 x106 Aag2 cells in 1 
ml L-15/10% FBS added to transfection mix in a 12-well plate. 
Cell Harvest 100 µl 2x DB  
Lysate Preparation Sonication for 3x 10 seconds, boil at 95°C for 5 minutes. 
   
 Tubulin Strep-II tag 
Primary Antibody Rabbit anti-human alpha 
tubulin antibody (AbCam), 
1:2000 
Mouse anti-Strep-II 
antibody (Qiagen), 1:2000 
Secondary Antibody Goat anti-rabbit IRDye 680CW 
(LI-COR Biosciences), 1:24000 
Goat anti-mouse HRP-
conjugated antibody (Dako), 
1:10000 
 
 
The research group that developed the insect expression vectors used for our study also found 
some DENV-2 proteins difficult to express in Aag2 cells, with the structural proteins E and prM 
remaining undetectable despite extensive optimisation (personal communication, Dr Priya 
Shah).  Individually expressed proteins may not localise or fold as they do when expressed 
as part of a polyprotein in an infection context. Certain proteins may need their surrounding 
proteins or transmembrane domains in order to be cleaved correctly to exhibit their functions, 
as has been discovered for NS5 which requires proteolytic processing from the DENV 
polyprotein in order to degrade STAT2 (Ashour et al., 2009). Given expression/detection 
difficulties, prM and E proteins were excluded from the screen as it is more likely that non-
structural proteins will be responsible for the immune antagonism. Although capsid is also a 
structural protein, it is important to include this in the assay as multiple functions beyond its 
classical structural role have been deciphered (Oliveira et al., 2017).  
 
Table 5.2.  Optimised immunoblotting conditions 
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The addition of MG132 improved protein detection by NIR during immunoblot optimisation. 
Although this does highlight that some of the expressed DENV-2 proteins are being degraded 
to a degree within the cell, this condition was not followed through as it does not reflect the 
samples that are used for studying IMD pathway induction by RT-qPCR analysis. The use 
ECL allowed all proteins to be visualised without the addition of MG132, therefore MG132 was 
eliminated from subsequent experiments. 
 
The variation of IMD signalling levels between screen experiments was quite considerable 
and could be the result of a multitude of experimental and biological factors. The Aag2 cells 
in each experiment may have been in different states, including passage number and stress 
levels which may have potentially impacted the immune signalling pathways. However, it is 
more likely that the variation arose from lack of assay robustness and reproducibility, 
highlighting the need for further optimisation of the RT-qPCR platform. Reverse transcription 
and qPCR reactions were conducted in very small volumes which may be advantageous with 
regards to the cost of running the assay but to the detriment of the quality, as it increases the 
chance of error at multiple stages. This could be overcome by scaling up the reactions and 
inclusion of an internal reference dye such as ROX™ in the qPCR reactions for sample 
normalisation, would eliminate another factor of variation. The addition of an internal reference 
dye would be of particular importance should the experiments continue to be conducted in the 
current small volumes. Another possibility would be to switch to a one-step RT-qPCR system 
which reduces the potential variability introduced when setting up separate RT and qPCR 
reactions.  
 
When re-optimising qPCR conditions, it will be important to determine the limits of detection 
for each primer set. This is particularly important for unstimulated samples where there are 
very low levels of AMP RNA transcribed in the cells to ensure that values obtained from these 
samples are representative of the levels present and not due to non-specific amplification, as 
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observed for Cecropin B (Figure 5.8). Accurate quantitation can only be achieved when 
reaction efficiency remains the same at both high and low template quantities.  
 
The results obtained from the IMD signalling screen experiments thus far suggest that NS4A 
may be in part or wholly responsible for Ae. aegypti IMD pathway suppression that has been 
observed in previous work from our laboratory (Figure 5.2). Although more optimisation may 
be needed to reduce the variability of RT-qPCR results between experiments, IMD signalling 
was consistently reduced in all experiments measuring the induction of pathway-specific 
AMPs. Therefore DENV-2 NS4A is a tentative IMD signalling antagonist and will be further 
tested using various molecular assays to confirm its inhibitory function. 
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CHAPTER 6 
IMD Pathway Antagonist Validation Methods 
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6.1 Chapter Introduction 
 
In the previous chapter, DENV-2 NS4A was identified as a potential IMD pathway antagonist 
in Aag2 cells using our RT-qPCR screening platform. NS4A is a multifunctional, highly 
hydrophobic membrane protein that contains four transmembrane domains embedded within 
in the ER membrane (Figure 1.6; Miller et al., 2007). It is a small 16 kDa transmembrane 
protein comprising 150 amino acids in its uncleaved form. During infection, NS4A localises to 
the VRC and has been found to induce host membrane rearrangements (Miller et al., 2007). 
In mammalian cell culture NS4A also restricts host IFN production and signalling (Muñoz-
Jordán et al., 2003; Dalrymple et al., 2015; He et al., 2016), as discussed in section 1.5.6.1, 
and induces autophagy (McLean et al., 2011).  
 
The N-terminus of NS4A is cytoplasmic and has been found to interact with membranes 
potentially inducing membrane curvature and stabilisation (Hung et al., 2015a; Hung et al., 
2015b). Previous studies have demonstrated that the first transmembrane-spanning region is 
important for NS4A dimerisation (Stern et al., 2013; Lee et al., 2015), which may play a role 
in membrane alterations (McMahon and Gallop, 2005) and interactions with NS4B, and 
although these interactions cannot occur simultaneously both may be required at different 
stages of replication (Zou et al., 2015). The C-terminal transmembrane domain, also known 
as 2K, is a 23 amino acid signal peptide for directing the ER localisation of NS4B that is 
cleaved from mature NS4A by cellular proteases (Miller et al., 2007). Only mature NS4A 
lacking the 2K domain has been shown to induce ER membrane rearrangements during 
infection (Miller et al., 2007), which is the therefore the form of NS4A expressed from the 
plasmid constructs used in this project. 
 
The aforementioned virus-host interactions and functions of NS4A were elucidated in 
mammalian systems; only Shah et al. (2018) have recently investigated NS4A interactions by 
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proteomics in Ae. aegypti cell culture.  Before NS4A is analysed to establish the viral 
determinants of IMD inhibition and interacting host partner(s), the inhibitory function of NS4A 
on IMD signalling must first be confirmed by studying molecular events within the IMD pathway 
in the presence of the tentative antagonist.  
 
In this chapter, novel plasmid-based NS4A constructs were created for further IMD signalling 
studies designed to analyse the effects of NS4A expression on Rel2 nuclear localisation and 
the IMD and Rel2 cleavage events within the IMD pathway. 
 
6.2 NS4A Constructs for Further DENV-2 IMD Pathway Screen Experiments 
 
6.2.1 Generation of EGFP-NS4A  
From the DENV-2 IMD pathway antagonist screen, NS4A has been identified as a tentative 
antagonist eliciting a 30-40% and 31-70% reduction in IMD signalling measuring IMD-
validated AMP genes Defensin D and Cecropin D respectively (Figure 5.12). As Aag2 cells 
have a transfection efficiency of approximately 48% (Figure 3.6, parental Aag2), not every cell 
will express NS4A, therefore the IMD pathway will be fully functional in the remaining 
untransfected cells.  To increase the percentage of NS4A-positive cells a plasmid expressing 
EGFP-tagged NS4A was generated to enable fluorescent cell sorting of transfected cells into 
enriched NS4A-expressing cell populations. For this, NS4A was cloned into a pIEx-backbone 
vector containing the coding sequence for an N-terminal EGFP tag (cloning strategy in 
Appendix B), with successful cloning confirmed by colony PCR and Sanger sequencing.  
 
To test the expression of the NS4A-EGFP construct, the plasmid was transfected into Aag2 
cells and 48 hours post-transfection cells were examined by fluorescence microscopy. EGFP-
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NS4A expressing cells were positive for GFP, which was confirmed not to be due to 
autofluoresence through the lack of green cells in the mock transfected sample (Figure 6.1).  
 
6.2.2 Generation of pAc-MCO-NS4A(N)  
As DENV-2 NS4A is the tentative antagonist moving forward, it would be beneficial to improve 
the detection of NS4A for future work. To do so, an N-terminally Strep-tagged NS4A plasmid 
construct was generated. As no N-terminal Strep-tag cloning vector was available, it first had 
to be cloned. A sequence encoding two Strep-tags followed by an IgG hinge to allow 
 
 
 
 
 
 
Figure 6.1 pIEx-EGFP-MCO-NS4A expression in Aag2 cells. Aag2 cells were transfected with 
300 ng pIEx-EGFP-MCO-NS4A or mock transfected and imaged by fluorescence microscopy at 48 
hours post-transfection. 
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autonomous folding and a multiple cloning site (MCS) for gene insertion was inserted into a 
pAc-backbone vector and the resultant pAc-2xStrep(N) plasmid sequence was confirmed by 
Sanger sequencing. An N-terminally Strep-tagged NS4A vector, pAc-MCO-NS4A(N) was then 
created by inserting the MCO NS4A gene sequence into the MCS. 
 
The pAc-MCO-NS4A(N) construct was tested for NS4A expression in transfected Aag2 cells 
by SDS-PAGE and immunoblotting. This was tested alongside the pAc-MCO-NS4A plasmid 
used in screen experiments to compare expression and detection. Prior to cell lysis 
morphological differences were observed in the Aag2 cells transfected with different plasmids. 
Transfection of pAc-MCO-NS4A caused the majority of Aag2 cells to round up and detach 
from the vessel surface (Figure 6.2a), however this was not observed in pAc-MCO-NS4A(N)-
transfected cells, where the cells appeared healthy and attached, comparable to the 
morphology of Aag2 cells expressing the empty vector control. 
 
During immunoblot analysis, a 16 kDa protein was detected in the pAc-MCO-NS4A 
transfected sample (Figure 6.2b) as observed previously (Figure 5.7). Enhanced levels of 
NS4A protein detection was observed in pAc-MCO-NS4A(N) transfected cells when compared 
to those transfected with pAc-MCO-NS4A. However NS4A was detected as doublet protein 
bands at 16 kDa (Figure 6.2b) suggesting that NS4A expressed from pAc-MCO-NS4A(N) may 
be post-translationally modified, resulting in the detection of a slightly larger protein, whereas 
that expressed from pAc-MCO-NS4A may not. 
 
A change in cell morphology and the detection of a doublet suggest that pAc-MCO-NS4A(N)-
expressed NS4A does not elicit the same effects in Aag2 cells as that expressed from pAc-
MCO-NS4A, which may be indicative of a change in protein folding. 
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Identification of NS4A as a putative IMD antagonist was achieved using a plasmid expressing 
a C-terminally tagged version of NS4A (see chapter 5). Therefore to test the potential 
antagonistic function of the N-terminally tagged NS4A construct both N- and C-terminally 
tagged versions were tested for IMD signalling inhibition as conducted in the previous chapter 
(section 5.3). Immunoblot analysis showed that all proteins were expressed, with N-terminally 
tagged NS4A being more strongly detected than C-terminally tagged NS4A but is present as 
a doublet band (Figure 6.3a), as observed previously (Figure 6.2b). RT-qPCR data show that 
Figure 6.2 pAc-MCO-NS4A(N) and pAc-MCO-NS4A transfection and immunoblot detection. 
Aag2 cells were transfected with 3 µg pAc-MCO-NS4A or pAc-MCO-NS4A(N) and were imaged (a) 
and harvested 48 hours post-transfection. (b) Samples were subjected to SDS-PAGE and 
immunoblot analysis and visualised via ECL and NIR detection methods. 
(a) 
(b) 
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for C-terminally tagged NS4A, there was an average decrease in the level of induction of IMD 
compared to the EGFP control of 77% and 43% as measured by Defensin D and Cecropin D 
mRNA levels respectively (Figure 6.3b), consistent with previous results (Figure 5.12). 
However, this decrease in IMD signalling and potential antagonism was not observed in the 
presence of N-terminally tagged NS4A, with average percentage IMD induction levels of 115% 
for Defensin D and 117% for Cecropin D (Figure 6.3b). This result further suggests that N-
terminally tagged NS4A does not function similarly to C-terminally tagged NS4A, likely caused 
by a change in protein conformation due to the presence of the N-terminal Strep-II tag.    
 
 
 
 
 
 
 
 
 
Figure 6.3 IMD pathway induction of NS4A C- and N-terminally Strep-tagged proteins. (a) 
Immunoblot confirming NS4A expression from pAc-MCO-NS4A(N) and pAc-MCO-NS4A. 
Arrowheads indicate desired protein bands of correct size. (b) RT-qPCR analysis of IMD pathway-
stimulated and unstimulated Aag2 samples detecting validated IMD-specific genes Defensin D and 
Cecropin D in the presence of both NS4A constructs. Relative percentage induction values were 
normalised to the relative induction of IMD in the presence of EGFP. Error bars represent standard 
error of the mean. One-tailed student’s t tests conducted, * P<0.05. 
(a) (b) 
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6.3 IMD Pathway Antagonist Validation Assays 
 
6.3.1 Nuclear translocation of Rel2 
Activation of the Ae. aegypti IMD pathway through an unknown PRR initiates a cascade that 
leads to the nuclear translocation of the NF-κB transcription factor Rel2, which consequently 
induces the expression of a multitude of genes encoding immune effectors, including AMPs 
(Hoffman, 2003; Antonova et al., 2009). Rel2 is alternatively spliced into three isoforms: Rel2-
Long, Rel2-Short, and IκB-type (Shin et al., 2002). Rel2-Long is homologous to Drosophila 
spp. Relish and mammalian p105 and p100 (Shin et al., 2002), and is the predominant isoform 
responsible for the induction of AMPs such as defensins and cecropins (Antonova et al., 
2009). All Rel2-expressing plasmids used in this project express the Rel2-Long isoform. 
 
To validate the NS4A tentative antagonist, nuclear translocation of a plasmid-expressed 
tagged Rel2 protein will be studied in the presence of plasmid-expressed DENV-2 NS4A. A 
reduction in Rel2 nuclear translocation will indicate inhibition of the upstream IMD pathway. 
For this, an mCherry-tagged Rel2 construct was previously generated by Dr Kevin Maringer. 
 
Before testing Rel2 translocation in the presence of DENV-2 NS4A, the kinetics of 
translocation after IMD pathway stimulation must first be determined. In mammalian systems, 
NF-κB translocation has been reported to occur between 6-30 minutes after pathway 
induction, in various cell lines (Ding et al., 1998; Nelson et al., 2004; Ashall et al., 2009; Di et 
al., 2012). In Drosophila cell culture, nuclear translocation of the Rel2 homologue Relish has 
been observed at 15 minutes after IMD pathway stimulation with lipopolysaccharide (Cornwell 
and Kirkpatrick, 2001). There are currently no available data on Ae. aegypti Rel2 translocation 
kinetics. 
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Figure 6.4. mCherry-Rel2 nuclear translocation timecourse. Aag2 cells were transfected with 
mCherry-Rel2 and IMD signalling stimulated with HI E. coli 48 hours post-transfection. Images were 
captured on a fluorescent microscope at the times specified after IMD pathway stimulation. 
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Aag2 cells were transfected with mCherry-Rel2 and visualised under a fluorescent microscope 
after IMD pathway stimulation with HI E. coli at 24 hours post-transfection. Images were 
captured every 5 minutes after pathway induction. Microscopy analysis showed that mCherry-
Rel2 was successfully expressed and localised in the cytoplasm of transfected Aag2 cells 
(Figure 6.4). However, over a period of 0-85 minutes mCherry-Rel2 nuclear translocation was 
not observed. Before further testing and optimisation of this assay, other IMD signalling events 
were studied to determine the timings of IMD pathway activation post-stimulation. 
 
6.3.2 Rel2 and IMD cleavage assay 
To study the protein cleavage events within the IMD pathway, genes encoding IMD and Rel2 
proteins were previously cloned into a pIEx-backbone vector with a FLAG affinity tag for 
detection by Dr Kevin Maringer.  Studying the two cleavage events within the IMD pathway 
provides an additional method of validating the tentative antagonist as well as giving an insight 
into the antagonistic mechanism as to where in the pathway inhibition by NS4A occurs.  
 
pIEx-FLAG-IMD possesses a FLAG tag on the C-terminus therefore upon cleavage, the 31 
kDa IMD protein should be reduced to approximately 28 kDa, based on the cleavage of D. 
melanogaster IMD protein which has the N-terminal 30 amino acids cleaved after pathway 
activation (Paquette et al., 2011).  
 
Three Rel2 constructs were also previously generated; pIEx-Rel2(C)-FLAG with a C-terminal 
FLAG tag, pIEx-FLAG-Rel2(N) with an N-terminal FLAG tag and pIEx-Rel2ΔIκB, where the 
Rel2 inhibitory IκB domain has been deleted, therefore encoding constitutively active Rel2.  
 
pIEx-FLAG-IMD, pIEx-FLAG-Rel2(N) and pIEx-Rel2(C)-FLAG were initially tested for protein 
expression alongside the empty vector control pIEx-FLAG. IMD and Rel2(N) protein bands 
were successfully detected at approximately 33 kDa and 114 kDa respectively (Figure 6.5).  
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However, it is not clear if the C-terminally tagged Rel2 protein was expressed due to the 
presence of a non-specific band of similar size that can also be detected in the empty vector 
control and IMD samples.  
 
All three plasmids were then tested in a timecourse experiment to determine if and when 
cleavage can be detected after IMD pathway activation.  Plasmids were transfected into Aag2 
cells individually and at 48 hours post-transfection, IMD signalling was stimulated with the 
addition of HI E.coli. Stimulated samples were harvested 3, 6, 9, 12 and 24 hours post-
stimulation as well as a non-stimulated control sample (harvested at 24 hours post-
stimulation). The experiment included a pIEx-FLAG empty vector control to determine non-
Figure 6.5. FLAG-tagged Rel2 and IMD protein expression in Aag2 cells. Aag2 cells were 
transfected with pIEx-FLAG (empty vector control), pIEx-FLAG-IMD, pIEx-FLAG-Rel2(N), or pIEx-
Rel2(C)-FLAG and harvested 48 hours post-transfection. Samples were subjected to SDS-PAGE 
and immunoblot and detected by NIR. White arrowheads highlight detected bands that are of the 
correct size for the relevant protein. Black arrowhead indicates the expected size of the Rel2 C-
FLAG protein.   
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specific background bands and the pIEx-Rel2ΔIκB control, to indicate the size of cleaved Rel2 
protein when testing the pIEx-FLAG-Rel2(N) construct.  
 
pIEx-FLAG-IMD was successfully expressed although smaller cleavage products of the 
expected size were observed (Figure 6.6). In the unstimulated IMD samples, an additional 
band was present although the molecular weight was too high to be the uncleaved IMD 
protein. In case non-specific proteasomal degradation of IMD cleavage products was 
occurring, all samples were duplicated with the addition of the proteasomal inhibitor MG132, 
however this did not have any effect on protein detection. 
 
 
 
 
Figure 6.6 IMD cleavage assay timecourse. Aag2 cells were transfected with 300 ng of pIEx-
FLAG-IMD and IMD pathway was stimulated by the addition of HI E. coli 48 hours post-transfection, 
with or without MG132. Samples were harvested 3, 6, 9, 12 and 24 hours after IMD pathway 
stimulation. pIEx-FLAG was also transfected as an empty vector control.  
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N-terminally FLAG-tagged Rel2 was successfully expressed from pIEx-FLAG-Rel2(N) and 
was visualised in abundance in the 24 hour unstimulated samples (Figure 6.7a). Rel2(N) was 
also abundant in its cleaved form at approximately 64 kDa in all stimulated samples from 3-
24 hours post-IMD stimulation, which was confirmed by the Rel2ΔIκB control (Figure 6.7a). It 
was still unclear if Rel2(C) was being detected in its uncleaved form due to the presence of 
strong background bands of a similar size (Figure 6.7b). However, at 24 hours post 
stimulation, a protein of 35-55 kDa was observed. This may have been IκB, which has a 
molecular weight of approximately 50 kDa. However from this immunoblot alone, that 
conclusion cannot be made.  
 
Due to the number of background bands and especially those of similar sizes of the desired 
proteins, it cannot be concluded that IMD and Rel2(C) are being cleaved upon IMD pathway 
stimulation (Figures 6.6 and 6.7b). The variability of the abundance of tubulin between the 
samples with and without MG132 make it difficult to determine if MG132 helped enhance any 
of the desired proteins. In future experiments the harvesting method should be changed to 
spin down all cells within the sample to minimise the variation of the tubulin control. 
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Figure 6.7 Rel2 cleavage assay timecourse. Aag2 cells were transfected with 300 ng of (a) pIEx-
FLAG-Rel2(N) or (b) pIEx-Rel2(C)-FLAG and IMD pathway stimulated with the addition of HI E. coli 
48 hours post-transfection, with or without MG132. Samples were harvested 3, 6, 9, 12 and 24 hours 
after IMD pathway stimulation. pIEx-FLAG and (a) pIEx-Rel2ΔIκB were also transfected as controls.  
(a) 
(b) 
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6.4 Chapter Discussion 
 
Following the DENV-2 IMD pathway antagonist screen, progress was made towards creating 
DENV-2 NS4A constructs for further IMD signalling inhibition studies and testing methods for 
validating the tentative antagonist using pre-existing molecular tools generated in our 
laboratory.  
 
New plasmid constructs expressing NS4A with an N-terminal EGFP tag and NS4A with an N-
terminal Strep tag were created for further antagonist screen studies. Although these 
constructs successfully express their proteins (Figures 6.1 and 6.2b) the morphology of the 
cells expressing these plasmids are vastly different compared to the C-terminally Strep-tagged 
NS4A used in the screen experiments (Figure 6.1 and 6.2a). This, along with the presence of 
the N-terminally tagged NS4A doublet in immunoblots and lack of antagonism of IMD 
signalling observed by RT-qPCR (Figures 6.3a,b) suggest that NS4A expressed from these 
new constructs may be folding and functioning differently compared to NS4A(C). NS4A-EGFP 
must be tested for antagonism before being used for cell sorting to obtain an NS4A-expressing 
population of cells for further IMD signalling antagonism studies. Should NS4A-EGFP not elicit 
the same antagonistic effects as C-terminally Strep-tagged NS4A, it may be useful to tag 
EGFP on the NS4A C-terminus for testing.  
 
The morphology of the pAc-MCO-NS4A transfected cells is of concern as they round up and 
detach from the monolayer (Figure 6.2a). As the DENV-2 NS4A construct lacks the 2K domain 
and is therefore the active form of the protein that induces membrane rearrangement during 
viral infection, it is possible that the difference in morphology is a consequence of membrane 
disruption within the cells.  Another explanation could be that the presence of C-terminally 
Strep-tagged NS4A is toxic to the Aag2 cells and causing cell death. NS4A is being 
overexpressed out of infection context, therefore if the function of NS4A during infection is 
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toxic to the cell, other DENV-2 proteins may inhibit cellular stress responses, such as 
apoptosis, thereby lowering the toxic effects of NS4A. Lower levels of NS4A could be tested 
to try and reduce this morphological change. 
 
The expression of C-terminally Strep-tagged NS4A may induce cell death and therefore result 
in downregulation of many genes that could be reflected in a decrease in IMD pathway 
stimulation. Therefore it is crucial to validate any significant decrease of pathway signalling 
including that of NS4A, by co-expressing a fluorescent reporter protein, such as EGFP, 
alongside NS4A in dual transfection studies, to look at protein expression levels and rule out 
other reasons for a reduction in IMD signalling other than pathway antagonism. 
 
Any potential antagonists indicated from the screen results must be validated by different 
assays. One such method is through observing nuclear translocation of the IMD pathway Rel2 
transcription factor upon pathway activation. There are currently no published studies that 
have determined the kinetics of Rel2 nuclear translocation in an Ae. aegypti cell line, therefore 
a primary test was conducted using mCherry-tagged Rel2 to determine when translocation 
occurs after IMD stimulation. A previous study on the Drosophila spp. Rel2 homologue Relish 
shows that nuclear translocation after stimulation with lipopolysaccharide occurs as early as 
15 minutes (Cornwell and Kirkpatrick, 2001). In this project when analysing cellular localisation 
of mCherry-tagged Rel2, no nuclear translocation was observed within 85 minutes (Figure 
6.4). There are a few potentially reasons that could explain the lack of observed translocation. 
Small amounts of mCherry-Rel2 may have translocated to the nucleus within the experiment 
but were simply not observed due to the resolution of the fluorescence microscope used. 
Confocal microscopy, which offers greater resolution would allow lower levels of translocated 
protein to be observed. However, microscopy images from Relish and mammalian NF-κB 
studies show that nuclear translocation, at least in these systems, is very apparent (Cornwell 
and Kirkpatrick, 2001; Nelson et al., 2004).  
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It is also possible that the lack of nuclear translocation was due to interference of the mCherry 
tag. The tag may cause Rel2 to misfold, may be too large to allow nuclear translocation, or 
may interfere with the cleavage of the IκB domain. Replacing mCherry with smaller affinity 
tags such as V5 or HA tags may affect protein interactions and localisation to a lesser extent, 
although this would prevent the use of live cell imaging as cells would have to be fixed for 
immunofluorescence microscopy. The presence of any tag on a protein can potentially alter 
its functions and localisation, therefore the generation of antibodies against purified Rel2 
would be a valuable tool for this assay, future IMD pathway studies, and the vector community. 
 
A second assay for validating potential IMD pathway antagonist is the Rel2 and IMD cleavage 
assay. After being unable to determine the kinetics of Rel2 nuclear translocation, the FLAG-
tagged IMD and Rel2 constructs were subsequently tested to estimate the window of IMD 
pathway activation post-stimulation. After an initial timecourse experiment was conducted, 
analysing hourly IMD pathway stimulated samples for 24 hours showed no indication of protein 
cleavage with any of the constructs (data not shown), a smaller timecourse was conducted 
that also included the addition of MG132 to eliminate the possibility of proteasomal 
degradation of cleaved products. Immunoblot analyses suggested that cleavage products of 
the N-terminally FLAG-tagged Rel2 protein may have been observed, although this cannot be 
concluded with certainty due to the large number of non-specific background bands present 
(Figures 6.7a), which are of similar sizes to the full-length and cleaved proteins of interest. Re-
cloning Rel2 and IMD to be tagged with a different affinity tag such as V5 (Hanke et al., 1994) 
or HA may decrease the number of non-specific bands and improve protein identification. 
 
Results of the timecourse experiments suggested that the N-terminally FLAG-tagged Rel2 
protein was successfully expressed and was cleaved upon IMD pathway activation, although 
the varying levels of tubulin indicating differing amounts of cellular material in the samples 
introduced difficulty in fully interpreting the results. During this experiment, supernatant was 
  
 
 
147 
removed before harvesting the cells in 2xDB as the cell monolayer appeared fully attached.  
It is possible that the cellular responses elicited in the presence of MG132 may have caused 
cells to detach during supernatant removal, resulting in fainter tubulin bands in the MG132 
samples. This timecourse should be repeated but with samples harvested at shorter time 
points to determine when cleavage occurs and all cells should be scraped into the covering 
media and pelleted to avoid losing any loose or detached cells.  
 
Once greater assay specificity is obtained with the use of alternative epitope tags, and the 
expression and cleavage of Rel2 and IMD is confirmed, additional timecourse experiments 
can be conducted to narrow down the time window in which the cleavage events occur. This 
will allow the nuclear translocation experiments to be performed at more relevant time points 
such that nuclear translocation is observed and it will also give important insights into the point 
of the IMD pathway at which antagonism occurs. 
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CHAPTER 7 
Discussion 
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DENV is the most important arbovirus affecting humans (Guzman et al., 2010), posing an 
increasing threat due to the global expansion of its mosquito vectors.  There are currently no 
specific anti-DENV therapeutics and the only available vaccine has mixed efficacies 
depending on serotype, leaving vector control as the best option for controlling the spread of 
disease. This reinforces the importance of studying disease vectors, including mosquito 
immunity, for new approaches to develop genetically modified transmission-incompetent 
mosquitoes to curb the spread of disease. This project aimed to progress towards this goal by 
identifying DENV-2 protein(s) involved in the inhibition of Ae. aegypti IMD signalling.  
 
Although DENV virus-host interactions have been extensively studied in humans (Ngono and 
Shresta, 2018), this is not the case in the Ae. aegypti vector. A major obstacle faced by the 
vector community has been the lack of a reliable Ae. aegypti reference genome until 2018 
where the extensive efforts of a collaboration of researchers known as the Aedes Genome 
Working Group yielded the high-quality AaegL5 genome (Matthews et al., 2018).   Studies in 
vector systems also face other hurdles such as a lack of readily available, commercialised 
molecular tools, assays, and biologically relevant cell lines for virus-host investigations (as 
discussed in section 3.1). Therefore an objective within this project aimed to address this 
deficiency by completing the characterision of the parental Aag2 cell line and various 
derivatives, such that virus-host interactions in the mosquito can be studied in a standardised, 
fully-characterised Ae. aegypti cell line.  
 
7.1 Characterisation of Clonal Aag2-derived Cell Lines 
 
Our laboratory previously generated a panel of Aag2-derived single cell clones to create a 
homogeneous background for use in CRISPR-Cas9 gene editing experiments. Multiple 
characteristics of these cell lines were analysed, such as cell morphology, growth kinetics and 
the ability to support optimal arboviral replication, after which the Aag2-AF5 cell clone was 
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determined as being most representative of the parental Aag2 cell line for further experiments 
(Fredericks et al., 2019). The results presented in Chapter 3 (Figures 3.2, 3.3, 3.5) 
demonstrate the completed characterisation of these Aag2-derived cell lines, and has 
contributed to a manuscript recently submitted for publication, with the preprint currently 
available on BioRxiv (Fredericks et al., 2019).  The Aag2-AF5 cell clone has been made 
available through ECCAC, providing the vector and arbovirus communities with a 
standardised and fully characterised mosquito cell line for in vitro studies. 
 
Aag2 cells have previously been shown to be persistently infected with the insect-specific 
viruses PCLV and CFAV (Stollar and Thomas, 1975; Maringer et al., 2017). Understanding 
the effects of these persistent infections on arbovirus replication is essential for drawing 
conclusions when using these cells in arbovirus studies. Previous studies have suggested that 
arbovirus replication is reduced when cells are co-infected with insect-specific viruses (Kenney 
et al., 2014; Goenaga et al., 2015; Nasar et al., 2015; Romo et al., 2018). However the 
experiments performed in these studies involved acute infection of cells with both arboviruses 
and insect-specific viruses and therefore do not necessarily reflect the effects on arbovirus 
replication one may observe in cells persistently infected with insect-specific viruses. This 
project therefore aimed to address the effects of persistent infection of Aag2 cells on arbovirus 
replication. Studies to identify single cell clones containing persistent PCLV infection showed 
that two of the Aag2-derived clones, Aag2-AF10 and Aag2-AF12 have markedly lower levels 
of PCLV present (Figures 3.2 and 3.3), which has also been confirmed by RT-qPCR in early 
and late cell passages (Fredericks et al., 2019). This finding suggests that these cell lines may 
express host restriction factors that are actively suppressing PCLV and therefore may offer a 
platform for studying virus-host interactions to determine novel anti-viral host factors within 
Aag2 cells (Fredericks et al., 2019). As the Aag2-AF5 clone and Aag2-AF10 and -AF12 clones 
represent Aag2 cultures with high and low levels of PCLV replication respectively (Figures 3.2 
and 3.3), they were used to determine the impact of persistent PCLV infection on arbovirus 
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replication (Fredericks et al., 2019). The data suggests that replication of representative 
arthropod-borne flaviviruses, alphaviruses and rhabdoviruses was not significantly affected by 
persistent insect-specific virus infection (Fredericks et al., 2019). Therefore these Aag2-
derived cell clones likely provide a more representative model for studying the effects of 
persistent insect virus infection on arbovirus replication compared to methods performed in 
earlier studies that are not reflective of natural virus persistence (Kenney et al., 2014; Goenaga 
et al., 2015; Nasar et al., 2015; Romo et al., 2018).  
 
Based on the recent discovery of sex-specific gene splice variants in Ae. aegypti (Salvemini 
et al., 2013; Salvemini et al., 2014), primary experiments were performed on the parental Aag2 
cell line using primer sets to amplify sex-specific products (section 3.4). Based on PCR 
experiments in which primers were designed to amplify sex-specific fruitless and doublesex 
splice variants, no sex-specific spliced products were amplified and the data only confirm that 
the Aag2 cell line was of embryonic origin. As the Aag2 cells are not fully developed and have 
not yet fully differentiated to express their sex-specific gene splice variants, there may be other 
genes and/or pathways that are not yet fully representative of those in developed adult 
mosquito cells. Therefore although the Aag2 cell line is a valuable tool to study Ae. aegypti 
immune pathways and virus-host interactions in vitro, they are not representative of cells that 
are naturally infected in vivo. This emphasises the need for more relevant cell lines for in vitro 
studies. Cell lines originating from female adult mosquitoes would be more biologically 
relevant as only females are exposed to arboviruses through infected blood meals and are 
therefore responsible for transmission (Weaver and Barrett, 2004).  
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7.2 Characterisation of Indels in Previously Generated CRISPR-Cas9 Knockout 
Cell Lines 
 
Rel2-/- Aag2 cell lines would be of great importance for follow-on work from this project as they 
lack IMD functionality, thereby allowing experiments to observe the effect of IMD inhibition on 
viral replication to be conducted.  Due to the previously generated clones no longer exhibiting 
a knockout phenotype (sections 4.2 and 4.3), new Rel2-/- cell lines will have to be created. 
Due to the limited availability of reagents for screening and validating successful CRISPR-
Cas9 mutants in Ae. aegypti, a non-model organism, an alternative approach would have to 
be used to create new knockout cell lines using the CRISPR-Cas9 system. The previously 
used method involved knockout by NHEJ, simply creating a targeted double-stranded break 
using Cas9, which upon imperfect repair by the cellular machinery creates an indel. In an 
alternative approach, knockouts could be created by homology directed repair, where a donor 
template would be added to guide the controlled repair of the break created by Cas9. The 
donor sequence could therefore be used to insert selection markers, such as fluorescent 
proteins or antibiotic resistance genes to simplify selection and detection of gene knockouts. 
 
7.3 Identification of DENV-2 IMD Pathway Antagonists 
 
In this project DENV-2 NS4A has been identified by RT-qPCR as an unconfirmed IMD 
pathway antagonist in Aag2 cells. Although re-optimisation of this assay may be required to 
reduce variability observed between experiments and increase assay robustness, this 
validated Aag2 IMD signalling assay is a valuable tool for studying IMD pathway induction. 
Other groups to date have studied Ae. aegypti IMD signalling by measuring the expression of 
pathway components and AMPs by RT-qPCR (Sim and Dimopoulos, 2010; Barletta et al., 
2012) or by Drosophila luciferase reporter assays in Ae. aegypti cells (McFarlane et al., 2014). 
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However the authors did not validate their assays for specificity within the culture systems 
used, which is essential when using Drosophila-derived tools, given the differences in immune 
regulation between Drosophila spp. and Ae. aegypti (as highlighted in section 1.2).   
 
In the screen experiments, proteins are not expressed in their polyprotein context, which could 
lead to the proteins folding into a different confirmation than during a natural infection (as 
discussed in section 5.3). This could not only abrogate the natural antagonistic effect of the 
proteins but could also mean that any potential hits, such as NS4A as identified in this project, 
may not be a real antagonist. However, a study by Miller et al. (2007) indicated that plasmid-
expressed DENV-2 (New Guinea C strain) NS4A demonstrated the localisation and 
functionality of NS4A observed during a natural infection. Using fluorescence microscopy they 
showed that transiently expressed NS4A lacking the 2K domain, fused to EGFP (NS4A(-2K)-
EGFP) exhibited a dotted appearance within the cytoplasm and was co-localised with the ER 
protein calreticulin, suggesting that NS4A(-2K)-EGFP functioned similarly to NS4A(-2K) in the 
context of a natural infection by actively rearranging ER membrane structures. This was 
shown when tagging either the N- or C-terminus of NS4A(-2K), suggesting that transiently 
expressed NS4A outwith the polyprotein context and tagged with an EGFP fluorophore did 
not affect its folding, localisation or functionality. This indicates that transient expression of 
NS4A through plasmid transfection is potentially a viable method for studying the IMD 
antagonistic activity of the protein.  
 
As discussed in section 6.4, comparing Aag2 cell morphology after transfection with pAc-
MCO-NS4A, pAc-MCO-NS4A(N) or pIEx-EGFP-NS4A shows that the construct used in the 
IMD pathway antagonist screen experiments elicits a different effect than the two new 
constructs, suggesting a functional difference between the expressed proteins. This was 
further supported by measuring the levels of IMD signalling in the presence of the two Strep-
tagged NS4A proteins, showing that only the C-terminally Strep-tagged protein caused a 
  
 
 
154 
reduction in IMD signalling. Therefore it is crucial that future work includes analysing the 
localisation of NS4A proteins from all constructs by co-staining with an ER marker such as 
calreticulin to determine if the tagged proteins are re-arranging ER membranes and co-
localising in dot-like structures in the cytoplasm. As discussed in section 6.4, due to the effects 
NS4A(C) has on Aag2 cell morphology, smaller amounts of the plasmid may have to be 
transfected and for a shorter period of time in an attempt to keep the Aag2 cells adhered to 
coverslips for successful immunofluorescence analysis. 
 
Although infection with DENV-2 was previously shown to disrupt IMD pathway function 
(section 5.1.2), it is possible that none of the DENV-2 proteins will act as inhibitors in isolation, 
pending the confirmation of the inhibitory function of NS4A. An obvious next step would be to 
perform the IMD pathway screen using the existing DENV-2 replicon in place of individual 
plasmid transfections, as it produces a polyprotein encoding all viral non-structural proteins 
alongside a luciferase reporter gene. This experiment would establish whether multiple non-
structural proteins act in conjunction to antagonise the IMD pathway.  Furthermore, it would 
allow the NS5 protein to fold correctly, which only occurs following cleavage from a polyprotein 
(Ashour et al., 2009).   It is also possible that the IMD pathway antagonism exhibited by DENV-
2 is encoded, at least in part, by a functional RNA rather than a viral protein.  For example, all 
flaviviruses produce sfRNAs (Urosevic et al., 1997, Lin et al., 2004). These are produced as 
a result of incomplete genomic degradation at the 3’ UTR end by the cellular 5’-3’ 
exoribonuclease 1 (Xrn1) and have been shown to suppress other antiviral immune responses 
in mosquitoes, including RNAi and Toll (Moon et al., 2015; Pompon et al., 2017). Therefore 
DENV sfRNAs could also be tested in the screen for potential antagonistic functions. 
 
The DENV-2 antagonist screen has a number of notable limitations. Aag2 cells are the only 
cell line used, however use of another Ae. aegypti cell line would help to confirm that any 
effects observed in the screen are not cell line-specific. However, the only other readily 
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available immunocompetent Ae. aegypti cell line is the CCL125/ATC-10 cell line (Singh et al., 
1967; Walker et al., 2014), which is exceedingly difficult to work with and is derived from larvae 
rather than adult female mosquitoes. It is acknowledged in the field that there is a need for the 
generation of more Ae. aegypti cell lines. As well as cell cultures originating from adult female 
mosquitoes, cell lines derived from different tissues would be useful as varying immune 
responses have been observed in different organs upon DENV infection (Xi et al., 2008). A 
better alternative to testing multiple cell lines in vitro might be to verify key findings in vivo, 
which is possible with our existing collaborator Dr Rennos Fragkoudis (Pirbright Institute, UK). 
 
Another limitation is that the screen is based on DENV-2 proteins. Although DENV-2 is of 
great interest as it is associated with more severe disease as well as causing the most cases 
out of the four serotypes (Thomas et al., 2008), other serotypes could be used to determine if 
any effects observed are serotype-specific. Our research group has experience working with 
all four DENV serotypes and we have viral stocks of representative strains for each that will 
be used in future infection experiments and to clone proteins for biochemical analysis. 
 
7.4 IMD Pathway Antagonist Validation Methods 
 
To further study the level of inhibition DENV-2 NS4A elicits on the IMD pathway, an NS4A-
EGFP expression plasmid was cloned to FACS sort EGFP-positive cells and to obtain an 
NS4A-expressing Aag2 population. Although the construct has been tested for expression 
(Figure 6.1), it must also be tested for inhibition of IMD signalling and localisation using higher 
resolution microscopy before these experiments are conducted. It is likely that complete 
inhibition of the IMD pathway will not be achieved; viral antagonists work in symphony to target 
the pathways of the innate immune responses at multiple levels to suppress antiviral activity. 
However, a balance must be reached as total inhibition of the host defences would likely result 
in host elimination, which is also detrimental to virus survival (García-Sastre, 2017). 
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mCherry-Rel2 provides a tool for studying nuclear translocation and its inhibition by IMD 
pathway antagonists. As there are no Rel2 kinetics data published thus far, the initial test was 
conducted to determine when Rel2 translocation occurs in Ae. aegypti, however translocation 
was not observed (discussed in section 5.4). As this may be due to the size of the mCherry 
fusion protein, Rel2 could be tagged with smaller affinity tags such as V5, HA or Strep. In the 
study by Cornwell and Kirkpatrick (2001), the Drosophila Rel2 homologue Relish was studied 
by tagging its N-terminus and the C-terminal IκB domain with FLAG and V5 tags respectively. 
In this project the FLAG tag resulted in numerous non-specific bands at sizes similar to the 
proteins of interest, therefore the FLAG tag may have to be avoided due to this non-specificity.  
 
Mammalian NF-κB oscillates between the cytoplasm and nucleus (Nelson et al., 2004), with 
initial nuclear translocation observed from 6 to 30 minutes after pathway activation, depending 
on the cell culture system (Ding et al., 1998; Nelson et al., 2004; Ashall et al., 2009; Di et al., 
2012). The activation of inhibitor kappa B kinase (IKK) leads to the phosphorylation of IκB 
(DiDonato et al., 1997) and NF-κB (Sakurai et al., 1999; Jiang et al., 2003), leading to the 
ubiquitination and proteasomal degradation of IκB, allowing nuclear translocation of NF-κB 
dimers. NF-κB regulates gene transcription within the nucleus which also involves the 
expression of free IκBα (Sun et al., 1993), creating a negative feedback loop.  Free IκBα, 
which contains a nuclear export signal, binds to nuclear NF-κB, causing the complex to 
translocate back to the cytoplasm (Arenzana-Seisdedoset et al., 1995) where it is once again 
a target for IKK phosphorylation. It is unknown if Ae. aegypti Rel2 also translocates back to 
the cytoplasm as the inhibitory IκB domain is cleaved in the cytoplasm and potentially 
degraded by the proteasome. Therefore it would be interesting to use the tagged Rel2 
constructs to determine whether Rel2 also oscillates between the nucleus and cytoplasm in a 
similar manner to mammalian systems and if so, by what mechanism.   
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7.5 Future Directions 
 
Once the IMD pathway antagonist has been validated, the next step in the project would be 
to identify the host proteins targeted by DENV-2 to inhibit IMD pathway induction. The binding 
partners of the DENV-2 IMD pathway antagonist could be identified by immunoprecipitation 
followed by mass spectrometry analysis of any proteins that are specifically pulled down by 
the DENV-2 antagonist(s). Virus-host protein-protein interactions and protein co-localisation 
can be confirmed by immunoprecipitation and immunofluorescence microscopy. Shah et al. 
(2018) have recently published work on identifying DENV virus-host interactions for each of 
the viral proteins in both Ae. aegypti and human systems, therefore this data could also be 
used to potentially identify interaction partners.  However, the caveat with these data is that 
these interactions have been determined in IMD unstimulated Aag2 cells. 
 
To study the effect of the IMD pathway on DENV and other arboviruses, new CRISPR-Cas9 
generated knockout cell lines will have to be generated. Before the CRISPR-Cas9 
experiments can be planned, the antibiotics for selection must first be determined. Puromycin, 
hygromycin B, blasticidin, zeocin and geneticin (G-418) have already been shortlisted for 
testing based on the literature as they have been used previously in D. melanogaster or other 
insect cells (Iwaki et al., 2003; Makridou et al., 2003; Kunzelmann et al., 2016) and data from 
our collaborator Dr Rennos Fragkoudis. Antibiotic kill curve experiments will be conducted 
using Aag2-AF5 cells, the parental clone used for generating all CRISPR-Cas9 mutants, to 
determine which antibiotics are able to kill the cells. The efficiency of cell killing, minimum 
effective antibiotic concentration and optimal timeframe will also be determined. Two selection 
antibiotics will be needed to generate both single and double knockout cell lines.  
 
sgRNAs will then be designed, using online tools such as CasFinder or E-CRISP (Aach et al., 
2014; Heigwer et al., 2014). Mutants resistant to the selection agent used (which will 
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presumably contain the resistance gene and hence an indel in the desired region), will then 
be screened for loss of function. Putative Rel2 knockouts will be screened for the induction of 
IMD-regulated genes such as Defensin D following immune stimulation using the established 
assays. Functional complementation experiments, in which the deleted genes are 
reintroduced into the knockout cells by transient transfection, will also be conducted to confirm 
that the observed phenotypic differences are specific and not due to off-target effects. 
 
The region of NS4A responsible for IMD pathway inhibition will be determined by creating 
plasmids that express truncated forms of NS4A, followed by generating constructs with 
minimal mutations in the mature NS4A sequence to eliminate the inhibitory function yet 
retaining all other known protein functions (section 6.1). Plasmid constructs will be transiently 
expressed in Aag2 cells and analysed by microscopy to ensure correct localisation as an 
indicator of maintaining functions observed within infection context, and by RT-qPCR to 
analyse IMD signalling levels to determine lack of mutant NS4A IMD pathway antagonism.  
 
The NS4A protein sequences of DENV-1-4 will be aligned to identify any conserved 
sequences within the region responsible for antagonism. Plasmids encoding NS4A of the 
remaining serotypes will then be generated and mutations introduced into the conserved 
regions. As above, WT NS4A and mutant NS4A plasmids will be analysed by microscopy to 
determine localisation and function and by RT-qPCR to analyse IMD signalling levels to study 
levels of IMD signalling. 
 
To validate the relevance of these findings in the context of a natural infection, a panel of 
DENV-2 mutants will be generated by reverse genetics, to contain NS4A with minimal 
mutations that disrupts the inhibitory function on the IMD pathway and analysed by microscopy 
to ensure the protein maintains all other functions. Growth kinetics of WT and mutant DENV-
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2 viruses will be studied in parental and Rel2-/- Aag2 cells with viral replication levels 
determined by plaque assay and RT-qPCR.  
 
Additional CRISPR-Cas9 experiments will also be conducted to knock out the DENV-2 
antagonist’s host target(s). The effect of this knockout on DENV-2 viral replication kinetics will 
be assessed in these cells by viral plaque assay and RT-qPCR. Ultimately, the effect of this 
knockout on the replication of other DENV serotypes will be compared, to test whether the 
effects on viral replication vary or are consistent across the serocomplex.  
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Appendix A – Table of reagents and manufacturers. 
 
Reagent Manufacturer 
Agarose Fisher Bioreagents 
Beta-mercaptoethanol Sigma-Aldrich 
Boric acid Sigma-Aldrich 
Bromophenol blue BDH Chemicals (Radnor, PA USA) 
Dried skimmed milk Marvel (St. Albans, UK) 
EDTA disodium salt Sigma-Aldrich 
Ethanol Fisher Bioreagents 
Glycerol Sigma-Aldrich 
Glycine Fisher Bioreagents 
Isopropanol Sigma-Aldrich 
Methanol Honeywell (Morris Plains, NJ USA) 
Sodium chloride (NaCl) Fisher Bioreagents 
Sodium deoxycholate Sigma-Aldrich 
Sodium dodecyl sulphate (SDS) Fisher Bioreagents 
Tris base Fisher Bioreagents 
Tris HCl Fisher Bioreagents 
Triton X-100 Sigma-Aldrich 
Tween 20 Sigma-Aldrich 
Urea Sigma-Aldrich 
Xylene Cyanol FF Sigma-Aldrich 
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Appendix B – Cloning strategy for pIEx-EGFP-MCO-NS4A 
 
 
 
 
 
Cloning strategy for pIEx-EGFP-MCO-NS4A. pIEx-EGFP(N) vector was digested using 
restriction enzymes XhoI and HindIII, whilst MCO NS4A was amplified from the pAc-MCO-NS4A 
plasmid. The PCR product was inserted into the vector in a direction-dependent manner using the 
In-Fusion® cloning system, followed by bacterial transformation and plasmid purification, resulting 
in pIEx-EGFP-MCO-NS4A, where MCO NS4A is tagged with EGFP on its N-terminus. 
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Appendix C – Cloning strategy for pAc-2xStrep(N) 
 
 
 
 
 
 
Cloning strategy for pAc-2xStrep(N). The insert for this construct was designed to contain two 
Strep-II tags, a multiple cloning site, an IgG hinge to allow autonomous folding, as well as the 15 
bp complementary to those of the digested vector for In-Fusion® cloning. Due to the size of this 
sequence, the insert was added along with the digested pAc vector to the In-Fusion® reaction as 
three overlapping primer pairs. The reaction mix was added to Stellar™ cells for bacterial 
transformation followed by plasmid purification, resulting in cloning vector pAc-2xStrep(N) for 
Strep-tagging proteins on their N-terminus. 
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Appendix D – Cloning strategy for pAc-MCO-NS4A(N) 
 
 
 
 
 
Cloning strategy for pAc-MCO-NS4A(N). pAc-2xStrep(N) vector was digested using restriction 
enzymes XhoI and HindIII, whilst MCO NS4A was amplified from the pAc-MCO-NS4A plasmid. The 
PCR product was inserted into the vector in a direction-dependent manner using the In-Fusion® 
cloning system, followed by bacterial transformation and plasmid purification, resulting in pAc-
Strep(N)-MCO-NS4A, where MCO NS4A is Strep-tagged on its N-terminus. 
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